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ABSTRACT 
 
THE ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-
GAMMA IN SURFACTANT CATABOLISM IN THE ALVEOLAR 
MACROPHAGE  
by 
Anna DeLane Baker 
Under the direction of Mary Jane Thomassen, Ph.D.   
December 2009 
 
Chair: Donald Hoffman, Ph.D. 
Department: Interdisciplinary Doctoral Program in the Biological Sciences, East 
Carolina University. 
 
 Pulmonary alveolar proteinosis (PAP) is a lung disease characterized by 
surfactant accumulation in the alveolar spaces and alveolar macrophages.  
Although PAP is rare, surfactant abnormalities occur in many lung diseases 
including acute respiratory distress syndrome, sarcoidosis, and asthma.  Studies 
have shown that surfactant accumulation in PAP patients results from insufficient 
catabolism by alveolar macrophages.  Research in PAP patients and 
granulocyte-macrophage colony-stimulating factor knockout (GM-CSF KO) mice 
revealed deficiencies in the transcription factor peroxisome proliferator-activated 
receptor-gamma (PPARγ) and downstream cholesterol transporter ATP-binding 
cassette G1 (ABCG1).  PPARγ regulates lipid metabolism in macrophages and is 
a prominent target of research in the fields of atherosclerosis and diabetes.   
 This study tested the hypothesis that PPARγ promotes catabolism of 
surfactant in alveolar macrophages through the transcriptional regulation of 
ABCG1.  Alveolar macrophages from macrophage-specific PPARγ knockout 
(PPARγ KO) mice accumulate surfactant and exhibit reduced expression of 
ABCG1 and reduced ABCG1-mediated cholesterol efflux.  These results directly 
link PPARγ-deficiency to surfactant accumulation and demonstrate that PPARγ 
regulates cholesterol efflux in alveolar macrophages.  We next investigated the 
expression of genes involved in the uptake and biosynthesis of cholesterol in 
PPARγ KO alveolar macrophages.  Expression of key cholesterol biosynthesis 
genes was suppressed, and cholesterol influx genes (scavenger receptors) were 
up-regulated.  These results suggested PPARγ regulates cholesterol metabolism 
in alveolar macrophages.  
 We next investigated the up-regulation of PPARγ in the GM-CSF KO 
alveolar macrophages by instilling mice with a Lentivirus vector containing 
PPARγ (Lenti-PPARγ).  Reconstitution of PPARγ promoted ABCG1 expression 
and ABCG1-mediated cholesterol efflux in the alveolar macrophages of GM-CSF 
KO instilled with Lenti-PPARγ.   
 Taken together, these observations support the hypothesis that PPARγ-
mediated transcriptional regulation of ABCG1 is critical to cholesterol metabolism 
and the maintenance of surfactant homeostasis overall.  Understanding the role 
of PPARγ in normal surfactant homeostasis provides insight into the 
pathophysiology of PAP and identifies a potential therapeutic target.  
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CHAPTER 1 
 
INTRODUCTION 
 
Pulmonary alveolar proteinosis (PAP) is an autoimmune lung disease 
caused by neutralizing auto-antibodies to granulocyte-macrophage colony 
stimulating factor (GM-CSF) (1).  The functional loss of GM-CSF manifests 
disease only in the lung, resulting in the filling of the respiratory tract of PAP 
patients with the lipoproteinaceous material called surfactant (2).  Inhibition of 
GM-CSF signaling impairs catabolism of surfactant in alveolar macrophages (3).  
Although PAP is a rare lung disorder, surfactant abnormalities are problematic in 
many inflammatory lung diseases, including acute respiratory distress syndrome, 
sarcoidosis, and asthma (4). 
Peroxisome proliferator-activated receptor-gamma (PPARγ) is a ligand-
activated nuclear transcription factor and a key regulator of lipid metabolism 
[reviewed by Tontonoz and Spiegelman (5)].  PPARγ is up-regulated by GM-CSF 
(6,7) and constitutively expressed in the alveolar macrophages of healthy 
individuals (6).  Neutralization of GM-CSF by auto-GM-CSF antibodies results in 
significantly reduced levels of PPARγ in the alveolar macrophages of PAP 
patients (6).  Alveolar macrophages of PAP patients have decreased expression 
of the lipid transporter ATP-binding cassette G1 (ABCG1).  Although the role of 
PPARγ in maintaining surfactant homeostasis is unknown, this data suggest that 
2 
PPARγ controls surfactant catabolism in alveolar macrophages via regulation of 
ABCG1.   
The work presented in this dissertation addresses the role of PPARγ in 
surfactant catabolism in alveolar macrophages.  We hypothesized that (1) PPARγ 
promotes surfactant catabolism by the regulation of the lipid transporter ABCG1; 
and (2) up-regulation of PPARγ will increase surfactant catabolism in PPARγ-
deficient alveolar macrophages and reduce the presence of lipid-engorged 
alveolar macrophages in the lung.  The following sections in this chapter will 
review the current literature on surfactant metabolism, alveolar macrophages, 
and the regulatory functions of PPARγ with a specific emphasis on lipid 
metabolism. 
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Lung Health and Immunity 
 
Air drawn into the human body travels through the nose and mouth, 
trachea, bronchi, and bronchioles terminating in the alveoli where exchange of 
oxygen and carbon dioxide occurs.  Alveoli require a lipid-rich material called 
surfactant to reduce surface tension and to stay open.  Type I epithelial cells 
occupy 90% of the alveolar surface area and are the primary site of gas 
exchange (8).  Type II epithelial cells are nearly equal in number to type I cells 
and are responsible for surfactant production.  Alveolar macrophages are also 
located in the alveolar space and regulate inflammation and the catabolism of 
surfactant.   
 The lungs contain many layers of defense including the mucociliary 
clearance system, innate immune system, and adaptive immune system to 
control inflammation and infection from continuous exposure to foreign debris, 
pathogens, and bacteria from the environment.  The mucociliary clearance 
system cleans the lining of the lung by the movement of the cilia in the 
respiratory epithelium pushing debris towards the pharynx and into the digestive 
system.  If a particular antigen or particle is not cleared by the mucociliary system 
and reaches the epithelial surface of the lung, the innate immune system 
responds through the activation of epithelial cells, neutrophils, dendritic cells, and 
monocytes and macrophages (9).  The adaptive immune system in the lung is 
complex and depends greatly on the targeted pathogen.  Three major players are 
4 
generally involved: dendritic cells, T cells, and B cells (10).  The adaptive 
immune system promotes clonal expansion of antigen-specific effector cells in 
response to a challenge. 
The term “macrophage” refers to cells differentiated from monocyte 
precursors arising from hematopoietic stems cells in the bone marrow.  
Macrophages are located throughout the body and are distributed in most 
tissues.  Alveolar macrophages are terminally differentiated macrophages 
located in the alveolar space and are continually replaced by circulating 
monocytes.  Because of their location, alveolar macrophages are among the first 
responders for foreign debris and pathogens.  Alveolar macrophages play a 
major role in the health and immunity of the lung classically through the 
clearance of debris and initiation of inflammatory cascades.  However, the 
emerging role of alveolar macrophages in the maintenance of lipid homeostasis 
in the lung through the clearance of surfactant is the focus of this investigation.   
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Function, Composition, and Metabolism of Surfactant 
 
Surfactant is a lipoproteinacious material found at the air-fluid interface in 
the alveoli that serves to reduce pulmonary surface tension to increase the 
efficiency of breathing.  It is a mixture of 80% phospholipid, up to 10% neutral 
lipid (predominantly cholesterol), 10% protein, and less than 1% carbohydrate 
(11). Phosphatidylcholine makes up the majority of the phospholipids in 
surfactant of which nearly half is dipalmitoylphosphatidylcholine (DPPC), the 
main surface-active lipid in surfactant.  Phosphatidylcholine is associated with 
four surfactant apoproteins.  Surfactant-associated proteins B (SP-B) and C (SP-
C) are small, extremely hydrophobic proteins that contribute to the surface 
tension-lowering properties of surfactant (12).  Surfactant-associated proteins A 
(SP-A) and D (SP-D) are involved in the innate immunity of the lung (13).  They 
are members of the collectin family and contain carbohydrate recognition 
domains that bind oligosaccharides on the surface of microorganisms (14). 
While the complex organization and structure of surfactant remains 
unclear, the use of genetically modified mice has greatly advanced our 
understanding of the roles of surfactant-associated proteins.  SP-A and SP-D 
deficient mice exhibit increased susceptibility to infections (15-17).  SP-B 
knockout mice develop lethal respiratory distress (18).  Additionally, these mice 
exhibit deficient mature forms of SP-C, confirming the importance of SP-B in 
surfactant (18,19).    
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Surfactant is continuously produced and degraded in healthy lungs 
through a highly regulated system.  Surfactant pool size is regulated by the net 
synthesis, uptake, recycling, and catabolism of surfactant.  Alveolar type II 
epithelial cells (pneumocytes) produce, partially assemble, and secrete 
surfactant [reviewed by Serrano and Pérez-Gil (20)].  Upon secretion, lipid and 
protein transfer to the interfacial surfactant film in response to surface tension.  
Components are also assembled into tubular myelin and large and small 
aggregates in the alveolar space.  Surfactant synthesis is better defined than the 
clearance of surfactant for which two pathways have been described [reviewed 
by Hawgood and Poulain (21)].  Type II cells endocytose surfactant lipids and 
complexes and recycle them into new surfactant.  Alveolar macrophages 
phagocytose and degrade surfactant and are therefore identified as the primary 
site of surfactant catabolism.   
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Surfactant Abnormalities in Human Disease 
 
Although it is known that type II cells produce surfactant and alveolar 
macrophages catabolize surfactant, the complexities of surfactant metabolism 
and its role in human disease are not fully understood.  Surfactant abnormalities 
are problematic in many inflammatory lung diseases, including PAP, acute 
respiratory distress syndrome, sarcoidosis, and asthma (4).  Excesses or 
shortages in pulmonary surfactant disrupt normal lung function.  Conversely, the 
surfactant pool size and composition are affected by disease states (22-24).   
Infant respiratory distress syndrome (RDS) is a common example that 
emphasizes the importance of the surface tension-reducing properties of 
surfactant.  RDS occurs in premature infants whom have not yet produced 
surfactant.  Intra-alveolar surface tension is too great without surfactant and the 
alveolar airspace collapses.   
At the other end of the spectrum, patients with the lung disease PAP have 
a build-up of surfactant in the alveolar spaces and alveolar macrophages.  Given 
that PAP patients produce normal levels of surfactant and no type II cell 
abnormalities have been observed, the accumulation of surfactant has been 
linked to reduced surfactant clearance by the alveolar macrophages (25-28).  
Investigation of the GM-CSF knockout (GM-CSF KO) mouse, which provided the 
initial evidence for GM-CSF involvement in surfactant homeostasis, has greatly 
contributed to the understanding of PAP pathogenesis (29,30).  Although PAP is 
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a rare lung disease, it provides a unique opportunity to investigate the regulation 
of surfactant with regard specifically to surfactant catabolism.   
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Overview of PAP 
 
PAP is a lung disease characterized by the pathogenic accumulation of 
surfactant in the lungs.  There are three forms of PAP: congenital, secondary, 
and idiopathic.  Congenital PAP is a genetic disorder resulting from defects in 
either the SP-B or GM-CSF receptors (31,32).  Secondary PAP is typically a 
result of inflammatory systemic diseases or hematological cancers and is 
generally resolved upon treatment of the primary disease (33-35).  Idiopathic 
(acquired) PAP, the focus of this thesis, is the most common form of PAP, 
accounting for 90% of the documented cases (36-39).  It is an autoimmune 
disease in which the patients produce neutralizing auto-antibodies to GM-CSF 
(1) with an estimated prevalence of 3.7 cases per million (40).  Interruption of 
GM-CSF signaling results in insufficient surfactant catabolism characterized by 
the accumulation of surfactant aggregates, the formation of foamy alveolar 
macrophages, and ultimately diminished air space within the alveoli (3).  The loss 
of biologically active GM-CSF manifests disease only in the lung, as GM-CSF is 
required for terminal differentiation of alveolar macrophages but not other tissue 
macrophages (41).  The resulting accumulation of surfactant in the lungs is 
consistent with a direct role of GM-CSF in surfactant catabolism (26).   
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Pathophysiology of PAP 
 
Many reports following the initial description of the lungs of PAP patients 
(2) have detailed the biochemical composition of the material accumulating in the 
alveoli (27,42).  All authors reported increased levels of phospholipids and 
protein.  The SP-A to phospholipid ratio is significantly increased in the sera and 
bronchoalveolar lavage (BAL) fluid from patients (43,44).  SP-D is also found at 
elevated levels in sera and BAL fluid of patients and represents a possible 
biomarker for disease severity in PAP (45).  Total amounts of SP-B and SP-C are 
found at increased levels in the lungs of patients with PAP (46).  However, the 
gene expression of all four proteins is unchanged supporting an impairment in 
turnover and clearance in pathogenesis (29).  Cholesterol is a major lipid 
component in surfactant and has been found at significantly elevated levels in the 
lungs of PAP patients (47-49).   
Since the accumulation of surfactant in PAP patients and GM-CSF KO mice 
has been linked to reduced surfactant catabolism (25-28), the emphasis of 
research has been on the alveolar macrophage.  Alveolar macrophages from 
PAP patients and GM-CSF KO mice have an activated phenotype resembling 
foam cells and are engorged with neutral lipid (50,51).  Microarray studies, 
confirmed by real time RT-PCR and immunocytochemistry, from our laboratory 
revealed that the nuclear transcription factor PPARγ was highly expressed in the 
alveolar macrophages of healthy individuals but deficient in PAP patients (6).  
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The role of PPARγ in regulating inflammation and lipid metabolism combined with 
the fact that PPARγ is up-regulated by GM-CSF makes it a prime target in the 
investigation of disease pathogenesis in PAP (6,7).  
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Diagnosis and Treatment of PAP 
 
Excess surfactant in the lungs of PAP patients causes shortness of breath, 
fatigue, and overall reduced pulmonary fitness.  Diagnosis of PAP is commonly 
confirmed by open lung biopsy.  A growing number of non-invasive alternatives 
have emerged, notably a serum anti-GM-CSF titer (52).  Over 70% of PAP 
patient mortality is due to respiratory failure (37).  
Standard therapy for PAP patients is a bilateral whole-lung lavage which 
removes excess surfactant but it does not to treat the underlying cause of 
pathogenesis and involves the risk of general anesthesia.  Treatment with 
exogenous GM-CSF targets the cause of the PAP and is currently in clinical 
trials.  The results of GM-CSF therapy are varied with resolution of disease in 
approximately 50% of the patients (53).  Non-responding patients have very high 
titers of neutralizing auto-antibodies to GM-CSF—perhaps too high for the 
exogenous GM-CSF treatments to overcome (54).  Depletion of B cells using 
monoclonal antibodies is being explored as a treatment for PAP.  Understanding 
the mechanisms involved in surfactant metabolism may lead to improved therapy 
for PAP and many other pulmonary diseases.  
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Overview of PPARγ 
 
The PPARs are a family of lipid-binding nuclear transcription factors that 
regulate inflammation, adipocyte differentiation, and glucose and lipid 
metabolism. Three isotypes of PPAR (alpha, delta/beta, and gamma) vary in 
tissue distribution and ligand affinity.  PPARγ is constitutively expressed at high 
levels in activated macrophages, adipose tissue, and the intestines [reviewed by 
Tontonoz and Spiegelman (5)].  The remaining discussion will be focused on the 
expression of PPARγ specifically in macrophages.   
Three isoforms of PPARγ (γ1, γ2, and γ3) are produced by alternative 
splicing events, PPARγ2 differing in length by an additional 30 amino acids at the 
5’ end. While PPARγ2 is less abundant overall than PPARγ1 (55), it is found at 
higher levels in macrophages and foam cells (56).  
Prostaglandin 15-d-PGJ2 and fatty acids are the major natural ligands for 
PPARγ (57,58).  Rosiglitazone, a thiazolidinedione, is a synthetic PPARγ agonist.  
Upon ligand binding, PPARγ heterodimerizes with retinoid X receptor (RXR) in 
the nucleus, forming a complex with co-activators which then bind to PPAR 
response elements (PPRE) in the DNA to promote transcription of downstream 
genes involved in lipid metabolism.   
PPARγ has also been shown to negatively regulate inflammation.  
Although the mechanisms are not fully understood, PPARγ exerts anti-
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inflammatory responses by antagonizing pro-inflammatory factors such as NF-κB 
and activator protein-1 (AP-1) [reviewed by Ricote and Glass (59)].  PPARγ 
reduces the DNA binding of NF-κB through three major mechanisms of 
transrepression including competitive binding of NF-κB co-activator complexes, 
direct binding of the p65 subunit of NF-κB, and promotion of Inhibitor of κBα 
(IκBα) (Figure 1.1).  PPARγ also transrepresses the pro-inflammatory actions of 
AP-1 by inhibiting mitogen-activated protein kinase (MAPK) activity.  Several 
models have suggested that the transrepression by PPARγ is gene and cell type-
specific.  More studies are needed to fully clarify the mechanisms of PPARγ 
transrepression. 
PPARγ is expressed in a variety of macrophages, such as thioglycollate-
elicited peritoneal macrophages, foam cells in atherosclerotic lesions, and 
alveolar macrophages from healthy individuals (6,60,61).  The data available on 
PPARγ is primarily focused on lipid and glucose metabolism and the promotion of 
foam cell formation in atherosclerotic lesions (7,62).  PPARγ is considered a 
potential therapeutic target for both diabetes and atherosclerosis due to its role in 
regulating lipid influx and efflux in macrophages (63).   
15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1  Mechanisms of PPARγ-mediated transrepression of NF-κB.  
PPARγ antagonizes NF-κB transcriptional activity by (A) competitively binding 
NF-κB co-activator complexes, (B) direct binding of the p65 subunit of NF-κB, 
and (C) promotion of IκBα.  Image was adapted from Ricote and Glass (59). 
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Cholesterol Biosynthesis, Uptake, and Efflux in Macrophages 
 
 Cholesterol is essential for membrane structure and organization, lipid 
rafts and cell-signaling, and endocytosis [reviewed by Maxfield and Tabas (64)].  
Excess cholesterol, on the other hand, can disrupt cell-signaling, cause 
membrane rigidity, and stimulate pro-apoptotic cascades.  Cells maintain 
cholesterol levels through the uptake of cholesterol from circulation and 
biosynthesis of cholesterol de novo (Figure 1.2).  The intracellular level of 
cholesterol is a critical part of the regulation of these processes [reviewed by 
Brown and Goldstein (65)].   
 Cholesterol is synthesized in the cell from acetyl-CoenzymeA through the 
mevalonate pathway.  In response to limited cholesterol, the nuclear transcription 
factor sterol response element-binding protein 2 (SREBP2) undergoes proteolytic 
cleavage, enters the nucleus, and promotes the transcription of all the cholesterol 
biosynthesis pathway enzymes including the rate-limiting enzyme 3-hydroxy-3-
methylglutaryl-coenzyme A reductase (HMGCR) (66,67).  HMGCR is the first 
committed step in the biosynthesis of cholesterol and a major site of feedback 
regulation (68,69).   
 Cholesterol obtained from the diet is carried in circulation by the low-
density lipoprotein (LDL).  In addition to cholesterol biosynthesis enzymes, in 
response to low sterol levels SREBP2 also promotes transcription of the LDL   
receptor (LDL-R) (70,71).  As cell cholesterol levels increase, LDL-R expression  
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Figure 1.2 Cholesterol biosynthesis, uptake, and efflux in macrophages. In 
response to limited cholesterol, SREBP2 promotes the transcription of important 
cholesterol biosynthesis enzyme HMGCR and cholesterol receptor LDL-R.  Free 
cholesterol is actively transported from macrophages by ABCA1 and ABCG1 to 
acceptor molecules Apo-AI and HDL, respectively.  CE, cholesteryl ester; FC, 
free cholesterol; SRE, sterol response element.  
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is reduced (72).  Further, LDL-derived cholesterol negatively regulates 
transcription of LDL-R and HMGCR through the SREBP2 pathway (71).  HMGCR 
is also subject to degradation in the presence of sterols through a sterol-sensing 
domain (73).   
 In addition to LDL-R, macrophages express several scavenger receptors 
that bind and internalize excess cholesterol in tissues.  Contrasting with the LDL-
R, scavenger receptor A-I (SRA-I) and CD36 are not inhibited by high 
intracellular cholesterol levels but rather are up-regulated in the presence of 
extracellular cholesterol bound to modified-LDL particles (74).  SRA-I and CD36 
are expressed on extrahepatic macrophages, such as those found in the 
vascular tissue.  The removal of cholesterol from macrophages is mediated by 
lipid transporters ABCG1 and ABCA1 which transfer cholesterol to the acceptor 
molecules high-density lipoprotein (HDL) and apolipoprotein A-I (Apo A-I), 
respectively.  Cholesterol is then recycled to the liver to make bile through a 
process called reverse cholesterol transport.  The accumulation of cholesterol in 
macrophages promotes foam cell formation and pro-inflammatory responses 
(75).  In fact, it has been demonstrated in models of atherosclerosis that 
“unrestricted” uptake of cholesterol by the scavenger receptors (due to high 
substrate levels) in cholesterol-rich tissues can result in intracellular cholesterol 
overload and foam cell formation when the efflux of cholesterol is insufficient or 
dysregulated (75).   
21 
 Cholesterol is primarily delivered to the lungs by lipoproteins (76).  
Although cholesterol is a relatively minor component, pulmonary surfactant is a 
major pool of cholesterol in the body.  Cholesterol is a functionally diverse lipid 
capable of influencing cell structure and signaling.   
 It has been shown that cholesterol levels are increased in the lungs of 
PAP patients while no difference was measured in the sera (47).  Cholesterol 
metabolites 3ß-hydroxy-5-cholestenoic acid (cholestenoic acid) and 27-
hydroxycholesterol (27-OH), however, were significantly elevated in the lungs 
and sera of PAP patients (47).  It was suggested that the increases were likely 
due to increased substrate supply rather than altered hepatic metabolism.  These 
results indicated that cholesterol metabolites could be a biomarker of pulmonary 
cholesterol homeostasis.  Combined with the presence of foam cells in the lungs 
of patients, these results also provided evidence that homeostasis of cholesterol 
catabolism may be disrupted in PAP.  Interestingly, the contribution of impaired 
cholesterol catabolism to the overall disruption of surfactant catabolism in the 
pathogenesis of PAP has not been specifically addressed.   
 While little is known of regulatory role of PPARγ in the lipid metabolism of 
alveolar macrophages specifically, data from other tissue macrophages have 
shown that macrophages are critical in maintaining the balance of cholesterol in 
circulation and in many tissues.  Cholesterol metabolism in turn is 
transcriptionally regulated by PPARγ through the expression of lipid transporters 
22 
Regulation of Lipid Receptors, Lipid Transporters, and Transcription 
Factors in Macrophages by PPARγ 
 
 Little is known of the regulatory role of PPARγ in the lipid metabolism of 
alveolar macrophages. Most of the research regarding PPARγ and lipid 
metabolism in macrophages has been done on other tissue macrophages such 
as peritoneal macrophages.  This work has shown that PPARγ transcriptionally 
promotes the efflux of cholesterol via transactivation of sterol-sensing 
transcription factor liver X receptor-alpha (LXRα) and lipid transporters ABCG1 
and ABCA1 (Figure 1.3) (77-79).  In a macrophage, cholesterol is metabolized 
into PPARγ ligands (oxidized fatty acids) (58) and LXR ligands (oxysterols) (80-
82) which transcriptionally activate both transcription factors and in turn, drives 
the removal of lipids from the macrophage via ABCG1 and ABCA1.  As 
described in the previous section, free cholesterol is transported by ABCG1 and 
ABCA1 to acceptor molecules HDL and ApoA-I and then on to the liver via 
reverse cholesterol transport (83,84).  The PPARγ-LXR-ABC cascade is critical to 
maintaining cholesterol efflux (85) as it is regarded as the rate-limiting step in 
reverse cholesterol transport.   
 Studies from knockout models have shown that the ABC transporters work 
synergistically and appear to have compensatory mechanisms.  When one ABC 
transporter is deficient, PPARγ and LXR ligands accumulate and induce 
expression of the other transporter (86,87).  ABCA1 deficient macrophages 
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Figure 1.3 PPARγ and LXR regulate cholesterol efflux.  Upon ligand binding, 
PPARγ and LXRα/β heterodimerizes with RXR and promotes the transcription of 
downstream genes ABCG1, ABCA1, ApoE, and CYP27A1.  The PPARγ-LXR 
cascade is critical to the maintenance of cholesterol efflux in macrophages.  This 
image was adapted from Argmann, et al. (88). 
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 exhibit increased ABCG1-mediated cholesterol efflux and ABCG1 deficient 
macrophages have increased ABCA1-mediated cholesterol efflux (86).  These 
studies also demonstrated that ABCA1 is less able to compensate for loss of 
ABCG1 as ABCG1-deficient mice develop more severe lipid accumulation in the 
lung (86,89,90). 
 Although scavenger receptor-mediated uptake of modified-LDL particles is 
complex and is not fully understood, it is known to be regulated in part by PPARγ: 
CD36 is directly up-regulated by PPARγ (61) while SRA-I is negatively regulated 
by PPARγ (60).  Cholesterol influx and efflux contribute to the overall cholesterol 
level in macrophages which in turn regulates the biosynthesis of cholesterol.  As 
PPARγ directly regulates cholesterol influx (via scavenger receptors) and efflux 
(via ABC transporters), it indirectly affects the biosynthesis of cholesterol in 
macrophages (Figure 1.4).   
Although PPARγ has been implicated as a critical mediator in cholesterol 
metabolism in various tissue macrophages, PPARγ may hold particular 
importance in cholesterol catabolism in alveolar macrophages given the amount 
of cholesterol in the lung.   
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Figure 1.4 PPARγ regulates cholesterol influx, efflux, and biosynthesis.  
PPARγ directly promotes transcription of genes involved in the movement of 
cholesterol in and out of the cell, including scavenger receptor CD36 and genes 
involved in cholesterol efflux LXRα, ABCG1, and CYP27A1, which influence the 
intracellular cholesterol level.  In turn, cholesterol levels regulate the biosynthesis 
of cholesterol through the expression of transcription factor SREBP2 and 
downstream targets HMGCR and LDL-R.  Therefore, PPARγ directly and 
indirectly regulates the influx, efflux, and biosynthesis of cholesterol in 
macrophages. 
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Statement of the Problem 
 
The expression of PPARγ is deficient in the alveolar macrophages of PAP 
patients and GM-CSF KO mice, which exhibit PAP-like pulmonary pathology and 
accumulate pulmonary cholesterol (6). However, the accumulation of surfactant 
has not been directly linked to the deficiency of PPARγ.  Further work in the 
laboratory on the alveolar macrophages of PAP patients and GM-CSF KO mice 
revealed that the expression of the lipid transporter ABCG1 was also deficient 
(51).  We therefore hypothesized that PPARγ promotes surfactant catabolism 
through regulation of ABCG1.  To address the hypothesis, we utilized a 
macrophage-specific PPARγ knockout (PPARγ KO) mouse model.   
  Chapter 2 addresses the hypothesis by utilizing PPARγ KO mice.  The 
specific objectives of Chapter 2 were to: (1) analyze the lipids accumulating in 
the alveolar spaces and alveolar macrophages of PPARγ KO mice, and (2) 
evaluate the expression of downstream PPARγ genes, including ABCG1, which 
may be involved in the catabolism of surfactant.   
Chapter 3 describes the generation of a Lentivirus vector containing the 
PPARγ sequence (Lenti-PPARγ).  We utilized Lenti-PPARγ to up-regulate PPARγ 
in primary murine and human alveolar macrophages in vitro.  Methods detailed in 
this chapter were critical to the in vivo experiments in Chapters 4 and 5.   
Chapter 4 discusses experiments that evaluate the effects of replacing 
PPARγ in vivo using Lenti-PPARγ on the regulation of cholesterol metabolism 
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genes.  The specific objectives of Chapter 4 were to: (1) up-regulate deficient 
expression of LXRα and ABCG1, and (2) investigate the expression of genes 
involved in cholesterol influx and synthesis in the alveolar macrophages of 
PPARγ KO mice. 
Chapter 5 investigates the reconstitution of PPARγ in PPARγ-deficient 
alveolar macrophages of GM-CSF KO mice. The specific purpose of Chapter 5 
was to investigate PPARγ-mediated changes on cholesterol efflux gene 
expression and clearance of surfactant in GM-CSF KO.  We hypothesized that 
surfactant catabolism is regulated by a PPARγ-ABCG1 pathway and that up-
regulation of PPARγ will increase surfactant catabolism and reduce the presence 
of lipid-engorged alveolar macrophages in the lung.   
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Abstract 
 
Surfactant accumulates in the alveolar macrophages of granulocyte-macrophage 
colony-stimulating factor knockout (GM-CSF KO) mice and pulmonary alveolar 
proteinosis (PAP) patients with a functional loss of GM-CSF resulting from 
neutralizing anti-GM-CSF antibody.  Alveolar macrophages from PAP patients 
and GM-CSF KO mice are deficient in peroxisome proliferator-activated receptor-
gamma (PPARγ) and ATP-binding cassette (ABC) lipid transporter ABCG1.  
Previous studies have demonstrated that GM-CSF induces PPARγ.  We 
therefore hypothesized that PPARγ promotes surfactant catabolism through 
regulation of ABCG1.  To address this hypothesis macrophage-specific PPARγ 
knockout (PPARγ KO) mice were utilized.  PPARγ KO mice develop foamy, lipid-
engorged Oil Red O positive alveolar macrophages.  Lipid analyses revealed 
significant increases in the cholesterol and phospholipid contents of PPARγ KO 
alveolar macrophages and extracellular bronchoalveolar lavage (BAL)–derived 
fluids.  Increased surfactant proteins A and D were detected in BAL fluid.  PPARγ 
KO alveolar macrophages showed decreased expression of ABCG1 and a 
deficiency in ABCG1-mediated cholesterol efflux to HDL.  Lipid metabolism may 
also be regulated by liver X receptor (LXR)—ABCA1 pathways.  Interestingly, 
ABCA1 and LXRβ expression were elevated indicating that this pathway is not 
sufficient to prevent surfactant accumulation in alveolar macrophages.  These 
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results suggest that PPARγ mediates a critical role in surfactant homeostasis 
through the regulation of ABCG1. 
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Introduction 
 
Pulmonary alveolar proteinosis (PAP) is a rare autoimmune lung disease 
characterized by neutralizing auto-antibodies to granulocyte-macrophage colony-
stimulating factor (GM-CSF) (1,91).  This loss of functional GM-CSF results in a 
filling of the alveolar spaces of the lungs with the lipoproteinaceous material 
called surfactant.  While PAP is a rare lung disorder, surfactant abnormalities are 
problematic in many lung diseases, including acute respiratory distress syndrome 
(ARDS), sarcoidosis, and asthma [reviewed by Sorensen (4)].  
Pulmonary surfactant is comprised of 90% lipid, 10% protein, and less 
than 1% carbohydrate. Phospholipids are the major lipid in surfactant and are 
associated with four surfactant-associated proteins (SP-A, -B, -C, and –D). SP-B 
and SP-C contribute to the surface tension lowering properties of surfactant and 
SP-A and SP-D are actively involved in the innate immunity of the lung [reviewed 
by Trapnell and Whitsett (92)].  Other lipids associated with surfactant include 
cholesterol, triglycerides, and free fatty acids.  Cholesterol is the major neutral 
lipid (up to 90%) in pulmonary surfactant (93).  Surfactant is produced by type II 
pneumocytes and two pathways have been described in the clearance of 
surfactant [reviewed by Hawgood and Poulain (21)].  Type II cells endocytose 
surfactant lipids and complexes and recycle them into new surfactant.  Alveolar 
macrophages phagocytose and degrade surfactant and are considered to be the 
primary cell involved in the clearance and catabolism of surfactant (3).  
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PAP patients produce normal levels of surfactant (25).  The accumulation 
of surfactant in the lungs of PAP patients is due to insufficient surfactant 
catabolism by alveolar macrophages (25,26,28).  Alveolar macrophages from 
PAP patients have an activated phenotype resembling foam cells and are 
engorged with neutral lipid, as evidenced by positive Oil Red O staining (50).  
The nuclear transcription factor peroxisome proliferator-activated receptor-
gamma (PPARγ) is constitutively expressed in the alveolar macrophages of 
healthy controls and is up-regulated by GM-CSF (6,7).  Our previous studies 
have shown that the alveolar macrophages of PAP patients and the GM-CSF 
knockout (GM-CSF KO) mouse model of PAP are deficient in PPARγ (6,51).   
While the role of PPARγ in surfactant catabolism in the lung remains 
unclear, PPARγ is known to directly and indirectly regulate many genes involved 
in cholesterol metabolism and transport including the nuclear transcription factor 
liver X receptor alpha (LXRα) and ATP-binding cassette (ABC) lipid transporters, 
ABCG1 and ABCA1 (51,77,78,94).  Studies have suggested that PPARγ 
deficiencies result in decreased expression of ABCG1 (51,77).  The deletion of 
ABCG1 in mice (ABCG1 KO) results in severe pulmonary lipidosis (89). 
Cholesterol and phospholipid accumulate and foam cell formation occurs in the 
macrophages of ABCG1 KO (84,86,89). Moreover, ABCG1 KO macrophages 
display reduced capacities to efflux cholesterol and phospholipid (83-85,95).  We 
therefore hypothesized that PPARγ may promote surfactant catabolism through 
regulation of the lipid transporter ABCG1.  To test this hypothesis, we 
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investigated the alveolar macrophages from macrophage-specific PPARγ 
knockout (PPARγ KO) mice. 
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Materials and Methods 
 
Mice. Animal studies were conducted in conformity with Public Health Service 
policy on the humane care and use of laboratory animals and were approved by 
the Institutional Animal Care Committee.  C57Bl/6 wild type (WT) mice were 
obtained from Jackson Laboratory (Bar Harbor, ME).  Macrophage-specific 
PPARγ KO mice have been previously described (96).  Bronchoalveolar lavage 
(BAL) cells were obtained as described earlier from 8–12 week old PPARγ KO 
mice and age- and gender-matched wild type C57Bl/6 controls (96). Briefly, the 
thoracic cavity was opened and the lungs were exposed. After cannulating the 
trachea, a tube was inserted and BAL was carried out with warmed (37°C) PBS 
in 1 mL aliquots x 5.  Except where indicated, sample number (n) refers sets of 
BAL cells pooled from 3-5 mice while BAL fluid was analyzed from individual 
mice.  Following previously established guidelines for analysis of acellular 
components of BAL fluid (97), analysis BAL fluid protein and lipid utilized 
samples with similar volumes recovered [ranging from 4.25-5.0mL for wild type 
and 4.1-4.8mL for PPARγ KO].  Cell viability was measured by trypan blue 
exclusion.  BAL cell differentials from all animals used in the experiments were 
stained with a Wright-Giemsa stain and revealed >90% macrophages.  Cytospins 
of BAL cells were stained with Oil Red O to detect intracellular neutral lipids. BAL 
cells were fixed in 4% paraformaldehyde, stained with Gill’s hematoxylin (Sigma, 
St. Louis, MI), and incubated in Oil Red O solution (Rowley Biochemical Inc., 
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Danvers, MA) overnight.  BAL cells were washed in 85% propylene glycol and 
mounted in Mount-Quick aqueous mounting medium (Daido Sangyo Co., Tokyo, 
Japan).  Oil Red O positivity was quantified by counting 100 cells on each 
cytospin slide from C57Bl/6 and PPARγ KO mice.   
 
RNA purification and analysis.  Total RNA was extracted from the cells by the 
RNeasy protocol (Qiagen, Valencia, CA).  Expression of mRNA was determined 
by real-time RT-PCR analysis using the ABI Prism 7300 Detection System 
(TaqMan; Applied Biosystems, Foster City, CA) according to the manufacturer's 
instructions.  RNA specimens were analyzed in duplicate using primer sets for 
mouse LXRα (Mm00443454), LXRβ (Mm00437262), ABCA1 (Mm00442646), 
ABCG1 (Mm00437390), CYP27A1 (Mm00470430), and APOE (Mm00437573) 
(Applied Biosystems).  Relative gene expression was quantified as described 
(98).  Briefly, the control group (C57Bl/6) values were calculated by subtracting 
the raw cycle (CT) data for the housekeeping gene (GAPDH, 4352339E) from 
the cycle data for the gene of interest.  The ensuing values (∆CT) were averaged 
and normalized to 1.0.  Data from PPARγ KO were quantified in a similar fashion 
and expressed as fold change in gene expression relative to wild type.  For these 
experiments, BAL cells were isolated from individual PPARγ KO mice and 
compared to pooled samples of C57Bl/6 BAL cells. 
 
39 
Cholesterol efflux assay.  Pooled BAL cells (3.5x105/well) were plated in 48-
well cell culture plates in complete DMEM media (Invitrogen, Carlsbad, CA) and 
maintained at 37°C and 5% CO 2.  Non-adherent cells were removed after one 
hour.  Cells were incubated for 24 hours in 2 µCi/mL of [1,2-3H(N)]-cholesterol 
(NEN, Perkin Elmer, Waltham, MA), equilibrated in serum free media for 24 
hours, and incubated in the presence of 10% fetal bovine serum (FBS), 
apolipoprotein A-I (ApoA-I) (25 µg/mL) (Sigma), or HDL (25 µg/mL) (Intracel, 
Frederick, MD) for 24 hours.  Supernatant fluids were harvested and centrifuged 
at 1800rpm for 5 minutes to remove cellular debris.  Cells were washed with PBS 
and lysed in 0.2 M sodium hydroxide (NaOH) with 0.1% SDS for 1 hour at room 
temperature.  Supernatant and cell-associated radioactivity was measured by 
liquid scintillation.  Cholesterol efflux was expressed as the percentage of 
radioactivity in the supernatant divided by the total radioactivity of the cells and 
supernatant.  Each assay was performed in duplicate and results from three 
independent assays were used to calculate percent efflux. 
 
Immunoblotting.  Equal volumes of BAL fluid were used for analysis of 
surfactant protein.  For analysis of BAL cell protein, samples were loaded based 
on equal total protein determined using a modified Lowry assay (Dc Protein 
Assay, Bio-Rad Laboratories, Hercules, CA).  Gels were eletrophoresed under 
reducing conditions using a 10% Bis-Tris gel (Bio-Rad) with MOPS buffer 
(Invitrogen).  The following primary antibodies and dilutions were used: 1:500 
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ABCG1 (sc-11150) and 1:500 ABCA1 (sc-5491, Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA); 1:5000 SP-A (AB3420) and 1:2000 SP-D (AB3434, Millipore, 
Billerica, MA). Bands corresponding to ABCG1 were normalized to β-actin as the 
loading control and the intensity of the protein bands were quantified using 
ImageQuant TL (GE Healthcare, Little Chalfont, England). Bands corresponding 
to ABCA1 were analyzed in the same manner using ImageJ.   
 
Lipid extraction.  Lipid analysis was carried out on sets of pooled BAL cells and 
1mL aliquots of BAL fluids with similar effluent volumes.  Total lipids were 
extracted using a modified method of Bligh and Dyer in HPLC-grade 
chloroform/methanol/1M sodium chloride (NaCl) (2/1/1.25, v/v/v) (Sigma) (99).  
The organic phase was obtained by centrifugation at 1500rpm.  Lipids were dried 
under a gentle stream of nitrogen gas.  The Phospholipids C kit (Wako Pure 
Chemicals, Osaka, Japan) was analyzed according to manufacturer’s 
instructions.  Phospholipid content was expressed as mg phospholipid per mg 
total protein. 
 
Cholesterol content analysis.  Sets of pooled BAL cells and BAL fluid samples 
with similar effluent recovered were analyzed for cholesterol content using the 
Amplex Red Cholesterol Assay (Invitrogen) according to the manufacturer’s 
protocol.  Cells and aliquots of cell-free BAL fluid were assayed in serial dilution 
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in 96-well plates.  Cholesterol content was expressed as µg cholesterol per mg 
total protein. 
 
Statistical analysis.  Data were analyzed by Student's t-test using Prism 
software (GraphPad, Inc., San Diego, CA). Significance was defined as p ≤ 0.05. 
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Results 
 
PPARγ deficiency results in lipid accumulation and dysregulation of lipid 
transporters in alveolar macrophages.  Wright-Giemsa staining revealed large 
foamy alveolar macrophages and Oil Red O staining showed that 88.8±1.7% of 
PPARγ KO alveolar macrophages stained positive, compared to 2.4±1.0% of wild 
type, indicating neutral lipid accumulation in the PPARγ KO (p<0.0001) (Figure 
2.1A).  Due to the lipid accumulation, we evaluated mRNA expression of the lipid 
transporters ABCG1 and ABCA1 which are known to be involved in lipid 
metabolism in macrophages and are downstream targets of PPARγ (100). 
ABCG1 mRNA was decreased 1.5-fold and in contrast ABCA1 was increased 
5.9-fold (Figure 2.1B).  Decreased ABCG1 and increased ABCA1 protein 
expression were confirmed at the protein level by immunoblotting (Figure 2.1C-
D).   
 
Surfactant lipids and proteins accumulate in the lungs of PPARγ KO mice.  
The composition of the lipid accumulating in the lungs of the PPARγ KO was 
determined by measuring both cholesterol and phospholipid levels in the alveolar 
macrophages and BAL fluids.  Compared to wild type mice, cellular content of 
free cholesterol was significantly increased in PPARγ KO mice (0.39±0.07 versus 
5.80±1.69 µg/mg protein) while the cholesteryl ester content was not significantly 
different (0.12±0.01 versus 0.58±0.29 µg/mg protein) (Figure 2.2A).  Free  
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Figure 2.1 PPARγ deficiency results in dysregulation of lipid metabolism in 
alveolar macrophages.  (A) Marked Oil Red O staining of alveolar macrophages 
from PPARγ KO indicate neutral lipid accumulation compared to wild type (n=3).  
(B) ABCG1 is decreased whereas ABCA1 expression is enhanced in PPARγ KO 
compared to wild type as measured by RT-PCR (n=6).  (C) ABCG1 protein is 
decreased and (D) ABCA1 protein is increased in PPARγ KO alveolar 
macrophages as shown in a representative immunoblot from one of two 
experiments. The numbers above the bands refer to sets of pooled BAL cells 
from each genotype.  The intensity ratios of the ABCG1 and ABCA1 protein 
bands to actin are indicated.  
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cholesterol was also elevated in the BAL fluid of PPARγ KO mice (59.6±5.7 
µg/mg protein) compared to wild type (17.8±1.3 µg/mg protein) (Figure 2.2B).  
Cholesteryl esters were not detected in the BAL fluid of wild type or PPARγ KO 
mice.  The cellular phospholipid content in PPARγ KO alveolar macrophages was 
significantly increased over wild type (0.03±0.01 versus 0.26±0.07 mg/mg 
protein) (Figure 2.2C).  Extracellular phospholipids were elevated in the BAL fluid 
of PPARγ KO mice (257.5±28.9 mg/mg protein) compared to wild type 
(174.2±16.0 mg/ mg protein) (Figure 2.2D).  Surfactant-associated proteins A 
(SP-A) and D (SP-D) were increased in the BAL fluid of PPARγ KO mice as 
shown by immunoblotting (Figure 2.2E).  
 
PPARγ deficiency results in decreased cholesterol efflux to HDL from 
alveolar macrophages.  The accumulation of cholesterol in the lungs and 
alveolar macrophages of the PPARγ KO and decreased expression of key 
cholesterol efflux mediators led us to evaluate the cholesterol efflux system.  
Baseline cholesterol efflux (no acceptor) was increased in the PPARγ KO 
alveolar macrophages (8.3±0.8%) compared to wild type (4.5±0.3%), and the 
overall cholesterol efflux to media supplemented with FBS was decreased in the 
PPARγ KO (59.5±1.7%) relative to wild type (70.5±3.5%) (Figure 2.3).  We next 
measured the efflux of cholesterol to acceptor molecules HDL and ApoA-I.  
Cholesterol efflux to ApoA-I in PPARγ KO (25.7±1.7%) was significantly  
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Figure 2.2 Surfactant lipids and proteins accumulate in the lungs of PPARγ 
KO mice. (A) Cholesterol levels of PPARγ KO alveolar macrophages (n=3 sets) 
and (B) BAL fluid (n=5) are increased.  Total and free cholesterol were measured 
and cholesteryl ester was determined by subtraction (90).  (C) The phospholipid 
content of PPARγ KO alveolar macrophages (n=4 sets) and (D) BAL fluid (n=11 
mice) are increased.  (E) Surfactant associated protein A (SP-A) and surfactant 
associated protein D (SP-D) were found at increased levels in the BAL fluid of 
PPARγ KO mice as shown by a representative immunoblot from one of three 
experiments.  The numbers above the bands refer to individual mice.  Following 
previously established guidelines for analysis of acellular components of BAL 
fluid (97), analysis BAL fluid protein and lipid utilized samples with similar 
volumes recovered.  
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increased over wild type (17.3±1.5%) and efflux to HDL was significantly 
decreased in PPARγ KO (46.2±1.5%) compared to wild type (56.7±3.6%).  These 
results suggest impairment of ABCG1-mediated cholesterol efflux.  
 
PPARγ deficiency results in dysregulated LXRα and LXRβ expression. 
Given the increased expression of ABCA1 in PPARγ KO alveolar macrophages, 
we next investigated the expression of the LXR transcription factors, which may 
regulate cholesterol metabolism in macrophages in part by mediating 
transcription of the ABC transporters (101).  RT-PCR analysis revealed a 1.7-fold 
decrease in LXRα mRNA and a 2.1-fold increase in LXRβ mRNA expression in 
PPARγ KO alveolar macrophages (Figure 2.4A).  RT-PCR analysis also revealed 
increased expression in apolipoprotein E (ApoE) (34-fold) and sterol 27-
hydroxylase (CYP27A1) (2.3-fold) mRNA in PPARγ KO alveolar macrophages, 
indicating that the LXR pathway is enhanced (Figure 2.4B).  
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Figure 2.3 PPARγ deficiency results in decreased cholesterol efflux to HDL 
from alveolar macrophages.  The efflux of 3H labeled cholesterol was 
measured in PPARγ KO alveolar macrophages and compared to wild type (n=3).   
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Figure 2.4 PPARγ deficiency results in dysregulated LXRα and LXRβ 
expression.  (A)  Gene expression of LXRα and LXRβ in BAL cells from wild 
type (n=4) PPARγ KO mice (n=6) were analyzed by RT-PCR.  LXRα mRNA 
expression is decreased in PPARγ KO alveolar macrophages in contrast LXRβ is 
increased.  (B) ApoE and CYP27A1 mRNA expression are increased in PPARγ 
KO alveolar macrophages (n=6) compared to wild type (n=5). 
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Discussion 
 
  In the present study we show that the targeted knockout of PPARγ in 
macrophages results in the accumulation of surfactant-like material in the 
alveolar spaces of the lung and within the alveolar macrophages.  This is the first 
report directly linking the deficiency of PPARγ to lipid accumulation in the lung.  
PPARγ KO alveolar macrophages phenotypically resemble those of PAP patients 
in that they are foamy and Oil Red O positive for neutral lipid accumulation (50).  
Additionally, surfactant components (surfactant-associated proteins, 
phospholipids, and cholesterol) are increased within extracellular BAL fluids.  
Finally, the alveolar macrophages of PPARγ KO mice have reduced expression 
of ABCG1 and exhibit reduced ABCG1-mediated cholesterol efflux to HDL.  Our 
results support the hypothesis that PPARγ-mediated regulation of ABCG1 
expression is critical for surfactant catabolism in alveolar macrophages. 
Previous studies have suggested that PPARγ is a key mediator of 
surfactant clearance and catabolism by alveolar macrophages (6,51).  Surfactant 
accumulates in alveolar macrophages of PAP patients.  PPARγ is deficient in the 
alveolar macrophages of these patients and is associated with the presence of 
neutralizing auto-antibodies against the hematopoietic growth factor GM-CSF (6).  
PPARγ deficiencies were also demonstrated in the GM-CSF KO mouse model of 
the disease (51).  
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GM-CSF also promotes cell survival, proliferation, and differentiation of 
alveolar macrophages and promotes the transcription of PPARγ in macrophages 
(7,29,102).  The biological loss of GM-CSF has been reported to impair the 
differentiation of alveolar macrophages through dysregulation of the transcription 
factor PU.1 [reviewed by Trapnell and Whitsett (92)].  It was further demonstrated 
that PU.1 is deficient in the alveolar macrophages of PAP patients and GM-CSF 
KO mice (103,104); however no deficiency in GM-CSF or PU.1 expression was 
observed in the alveolar macrophages of the PPARγ KO mice.  GM-CSF was up-
regulated 2.7±0.25-fold (n=5, p=0.02) while PU.1 expression was not different 
from wild type mice (n=3).  These data suggest that maturation of the PPARγ KO 
alveolar macrophages is not disrupted as it is in PAP patients and GM-CSF KO 
mice (92). This is consistent with current literature suggesting that although 
PPARγ is not necessary for the differentiation of monocytes, a variation in the 
expression levels of PPARγ may modulate differentiation (105-107). 
Consistent with the findings in PAP patients and GM-CSF KO mice 
(47,49,108-110), the PPARγ KO mice exhibit elevated levels of the major 
components of surfactant including cholesterol, phospholipid, and surfactant-
associated proteins in the BAL fluid and alveolar macrophages.  The alveolar 
macrophages from the PPARγ KO mice exhibited significantly increased 
cholesterol content comprised predominantly of free cholesterol.  Cellular 
deposition of free cholesterol is considered to be a pivotal step in foam cell 
formation (111) and is consistent with the foamy phenotype of the PPARγ KO 
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alveolar macrophages.  The pattern of lipid accumulation both in the alveolar 
space and alveolar macrophages of the lungs of PPARγ KO mice suggests 
deficient or incomplete surfactant catabolism by the alveolar macrophages.  
RT-PCR analysis of the PPARγ KO alveolar macrophages revealed similar 
gene expression patterns of downstream PPARγ targets to those previously 
reported from PAP patients and GM-CSF KO mice with decreased expression of 
ABCG1 mRNA (1.5-fold) and increased expression in ABCA1 mRNA (5-fold) 
(6,51).  These results are consistent with several studies indicating deficiency of 
one ABC transporter is compensated by the other transporter and is mediated by 
the sterol-sensing nuclear transcription factor LXR in response to the buildup of 
oxysterol ligands (87) or the oxidation of cholesterol metabolites by CYP27A1 in 
foamy macrophages (112).  The two isoforms of LXR, LXR alpha (LXRα) and 
LXR beta (LXRβ), have overlapping roles in promoting cellular cholesterol export 
through regulation of the ABC transporters and ApoE (101).   
In contrast to increased LXRα expression reported in PAP and GM-CSF 
KO (51), LXRα was down-regulated nearly 2-fold in the PPARγ KO mice.  The 
differential expression of LXRα, which is regulated in part by PPARγ (77), may be 
explained by the varying levels of PPARγ in these systems: PPARγ is deficient in 
PAP and GM-CSF KO and is absent in PPARγ KO.  This is supported by the 
finding that LXRβ expression, which is regulated independently of PPARγ (77), is 
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increased nearly 2-fold in the PPARγ KO alveolar macrophages.  The expression 
of LXRβ has not been reported in PAP or GM-CSF KO alveolar macrophages.   
While more study is needed to elucidate the possible mechanisms and 
differential regulation of the LXRs, it has been shown that the function and 
expression of the LXR isoforms are tissue-dependent (101,113,114).  LXRβ is 
expressed at higher levels than LXRα in macrophages and is more effective than 
LXRα at up-regulating ABCA1 in response to sterol ligands (115).  While the 
contributions of the individual LXR isoforms are unknown, as specific gene 
targets have yet to be identified, the LXR pathway overall is enhanced in the 
PPARγ KO, as evidenced by increased expression of downstream targets 
ABCA1 and ApoE.  We show that increased expression of the LXR pathway is 
not sufficient to maintain surfactant catabolism in the absence of PPARγ. 
The accumulation of cholesterol in the lungs and alveolar macrophages of 
PPARγ KO mice and the dysregulation of several cholesterol transport genes led 
us to investigate the efflux of cholesterol in PPARγ KO alveolar macrophages in 
vitro.  PPARγ promotes lipid influx and efflux in macrophages through 
transcriptional regulation of ABC transporters and LXRs.  ABCG1 mediates 
transport of cholesterol to extracellular acceptor HDL and ABCA1 transports 
cholesterol to lipid-free ApoA-I (83-85,116,117).  In the present study, ABCG1-
mediated cholesterol efflux to HDL was reduced and ABCA1-mediated efflux to 
ApoA-I was increased. Overall cholesterol efflux to FBS (10% serum) was 
decreased compared to wild type, consistent with the high levels of cholesterol in 
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the macrophages in vivo.  These findings indicate that the reduction in 
cholesterol efflux in the PPARγ KO alveolar macrophages may be due to 
deficient transporter mediated cholesterol efflux pathways, specifically transport 
mediated by ABCG1.   
Interestingly, similar patterns of cholesterol and phospholipid accumulation 
and altered lipid efflux have been reported in ABCG1 KO models (86,89).  A 
reduction in total cholesterol efflux and a specific reduction in efflux to HDL were 
noted in ABCG1 KO peritoneal macrophages (86). Importantly, the authors also 
noted significantly increased efflux to ApoA-I in ABCG1 KO indicating 
compensation by ABCA1.  Taken together, deficiencies in ABCG1 may result in 
dysregulated or insufficient cholesterol efflux and therefore cholesterol 
accumulation in the lung. 
A summary of the differential gene expression of various lipid regulators 
and transporters in the alveolar macrophages from PPARγ KO mice, GM-CSF 
KO mice, and PAP patients is presented in Table 2.1.  Comparison of the data 
supports the hypothesis that PPARγ-mediated regulation of ABCG1 is necessary 
to prevent the accumulation of surfactant.  Additionally, the LXR pathway is 
enhanced in all of the groups, as evidenced by increased expression in ABCA1.  
An interesting difference, however, is the expression of LXRα which is increased 
in PAP and GM-CSF KO (PPARγ-deficient) alveolar macrophages and 
decreased in the PPARγ KO model.  We speculate that lipid accumulation 
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Table 2.1  
Summary table of expression levels of key lipid regulator and transporter genes 
in the alveolar macrophages from PPARγ KO mice, GM-CSF KO mice, and PAP 
patients. 
 
Lipid Regulators PPARγ KO MICE GM-CSF KO MICE PAP PATIENTS 
GM-CSF Increased Not expressed (29) Decreased* (118) 
PPARγ Decreased Decreased (51) Decreased (6) 
ABCG1 Decreased Decreased (51) Decreased (51) 
ABCA1 Increased Increased (51) Increased (51) 
LXRα Decreased Increased (51) Increased (51) 
LXRβ Increased Not reported Not reported 
 
*GM-CSF mRNA is increased (118). However, protein is functionally reduced due to neutralizing antibodies 
against GM-CSF (1). 
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 activates the LXR-ABCA1 pathway as a compensation mechanism, and that in 
the absence of PPARγ, LXRβ is the predominant isoform driving the up-
regulation of ABCA1 and ApoE.  
In the PPARγ KO mouse model, the absence of PPARγ results in reduced 
expression levels of ABCG1 and LXRα.  Despite increased expression of LXRα 
and ABCA1 and increased ABCA1-mediated cholesterol efflux, surfactant 
components accumulate in the alveolar macrophages and BAL fluid of PPARγ 
KO mice.  Our results indicate that as part of surfactant catabolism, ABCG1-
mediated cholesterol efflux to HDL may be the major pathway for cholesterol 
efflux in alveolar macrophages.  Thus PPARγ-mediated regulation of ABCG1 
expression may be critical to the maintenance of surfactant homeostasis.  This is 
the first report directly linking PPARγ deficiency in alveolar macrophages to lipid 
accumulation in the lungs.  Understanding the role of PPARγ in normal surfactant 
homeostasis contributes to our knowledge of the pathophysiology of PAP and 
identifies a potential target for therapy.  
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Abstract 
 
The use of the Lentivirus expression system for gene delivery has gained 
significant interest due to its rapid, stable and long-term gene expression into a 
wide variety of cell types.  Herein, we have utilized this system to successfully 
generate a Lentivirus, (Lenti-PPARγ), which expresses human PPARγ, a 
transcription factor of the nuclear hormone receptor superfamily which is involved 
in lipid metabolism in macrophages.  Transduction of Lenti-PPARγ into several 
cell types including cell lines and primary murine and human alveolar 
macrophages isolated from bronchoalveolar lavage led to the efficient expression 
of PPARγ as confirmed by RT-PCR and immunoblotting.  Moreover, RT-PCR 
analysis revealed expression was dose-dependent.  These results demonstrate 
that this system provides a reliable approach to study gene expression.   
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Introduction 
 
Peroxisome proliferator-activated receptor-gamma (PPARγ) is a lipid-
binding nuclear transcription factor involved in lipid and glucose metabolism in 
macrophages.  Alveolar macrophages constitutively express high levels of 
PPARγ (6).  The alveolar macrophages from patients with the autoimmune lung 
disease pulmonary alveolar proteinosis (PAP) are deficient in PPARγ (6).  The 
biological loss of granulocyte-macrophage colony-stimulating factor (GM-CSF) 
due to a neutralizing auto-antibody results in the accumulation of surfactant in the 
lungs and alveolar macrophages of PAP patients (1,91).  GM-CSF has been 
shown to up-regulate PPARγ (7).  Therefore, we hypothesized that the GM-CSF-
PPARγ pathway is involved in the regulation of surfactant catabolism (Figure 
3.1).  In order to test this hypothesis, we have utilized a Lentivirus expression 
system to restore expression of PPARγ in the PPARγ-deficient alveolar 
macrophages of GM-CSF knockout (GM-CSF KO) mice, a well-established 
model for studying PAP (29).   
The most common mediators of gene delivery are DNA plasmids, 
liposome vectors, and recombinant viral vectors.  While DNA plasmids are 
unstable and liposome vectors can evoke inflammatory responses (119), 
recombinant viral vectors are robust and can be adapted to be non-disruptive to 
host cells.   
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Figure 3.1 Proposed pathway of interest.  The GM-CSF-PPARγ pathway in 
alveolar macrophages promotes the clearance of surfactant, particularly the 
cholesterol component, through the regulation of liver X receptor-alpha (LXRα), 
ABC transporters (ABC) ABCG1 and ABCA1, apolipoprotein E (ApoE), and 27-
hydroxylase (CYP27A1).  PPRE, PPARγ response element; RXR, retinoid X 
receptor. 
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The Lentivirus expression system offers many advantages.  In contrast to 
adenoviral-based vectors, recombinant retroviral vectors offer the unique 
capacity of delivering, integrating, and expressing genetic material in the host cell 
without undergoing lytic, destructive cycles of replication, making them ideal for 
targeting non-dividing cells (120).  Lentivirus has been adapted for gene therapy 
by the removal of essential wild type replication genes and the addition of self-
inactivating long terminal repeats (Figure 3.2).  Lentivirus vectors may be 
engineered to target specific cell types by pseudotyping the viral protein coat.  
Lentivirus-mediated integration is stable and heritable, unlike the adenoviral 
vectors which offer poor efficiency and transient expression of the delivered 
gene.  Additionally, Lentivirus is capable of transducing non-dividing cells, such 
as terminally differentiated alveolar macrophages.   
Herein, we have transduced primary murine macrophages resulting in the 
up-regulation of PPARγ, in vitro.  Additionally, preliminary experiments on human 
alveolar macrophages demonstrated the effectiveness of the Lentivirus system 
on primary human cells.  These results demonstrate an efficient, reliable 
technique for the up-regulation of PPARγ in primary macrophages for the further 
study of PPARγ in surfactant catabolism.   
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Figure 3.2 Production of live Lenti-PPARγ virus.  The Lentivirus plasmid 
containing the PPARγ sequence along with plasmids encoding for env, gag/pol, 
and rev genes were transfected into 293FT cells to produce live Lenti-PPARγ 
virus.  Image adapted from Malur, et al. (121).  SIN, self-inactivating; LTR, long 
terminal repeat; RRE, Rev response element; SA, splice acceptor; SD, splice 
donor; CMV, cytomegalovirus promoter, MCS, multiple-cloning site; SV40, 
Simian virus 40 promoter; BLSD, blasticidin.   
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Materials and Methods 
 
Mice.  Animal studies were conducted in conformity with Public Health Service 
(PHS) Policy on humane care and use of laboratory animals and were approved by 
the institutional animal care committee.  C57Bl/6 wild type (WT) mice were obtained 
from Jackson Laboratory (Bar Harbor, ME).  The GM-CSF KO mice were generated 
by Dr. Glenn Dranoff (29).  The mice have been backcrossed eight generations to 
C57Bl/6.   
 
Bronchoalveolar lavage (BAL).  Macrophages from 3-5 animals were pooled for 
each set of experiments.  Mice received ketamine (90 mg/kg) and xylazine (10 
mg/kg) intraperitoneally.  The thoracic cavity was opened and the lungs were 
exposed.  After cannulating the trachea a tube was inserted and bronchoalveolar 
lavage was carried out with warmed (37oC) PBS in 1ml aliquots.  Cytospins of BAL 
cells were stained with a modified Wright–Giemsa stain for differentials.  Viability 
was >95% as determined by trypan blue for all cell preparations. 
 
Peritoneal exudate cells.  To obtain peritoneal macrophages, mice were 
euthanized with Isofluorane.  Five mL of warmed PBS was injected 
intraperitoneally using a 23 gauge needle.  After exposing the peritoneal cavity, a 
small incision was made in the peritoneum and a transfer pipet was used to draw 
out the fluid.  Cells and fluid were pooled and processed as above.    
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Healthy control cell collection.  This protocol was approved by the Institutional 
Review Board, and written informed consent was obtained from all subjects.  
Healthy control individuals had no history of lung disease and were not on 
medication (n=3).  Alveolar macrophages were derived from BAL fluid obtained 
by fiber-optic bronchoscopy as described previously (122).  Differential cell 
counts were obtained from cytospins stained with a modified Wright's stain. 
Differential cell counts from BAL fluid indicated that >95% of healthy control cells 
were alveolar macrophages.  The mean viability of lavage cells was >95% as 
determined by trypan blue dye exclusion. 
 
Lentivirus construction and transduction.  A self-inactivating Lentivirus 
expression vector that was previously utilized in the generation of a stable cell 
line expressing the human parainfluenza virus type 3 C protein was used for 
these experiments (51,121).  cDNA corresponding to the human PPARγ 
sequence was cloned into the multiple cloning sites downstream of a CMV 
promoter using standard techniques as described (121).  The recombinant 
Lentiviral plasmid thus obtained was transfected into 293FT cells along with 
plasmids encoding the gag, pol and rev genes and a plasmid possessing the 
vesicular stomatitis glycoprotein (G) using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA).  At 72 hrs post transfection, cell culture supernatant containing 
the Lentivirus-PPARγ (Lenti-PPARγ) was collected and then purified by 
centrifugation at 27,000 rpm at 40C for 3.5 hrs.  The Lenti-PPARγ virus pellet was 
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resuspended in PBS and aliquots of 100µl were stored at -700C.  The 
concentration of Lenti-PPARγ virus was determined by a p24 ELISA (Cell 
Biolabs, San Diego, CA).  A Lentivirus expressing the enhanced Green 
Fluorescent Protein (Lenti-eGFP) was obtained using a similar protocol and was 
utilized as a control in experiments for the determination of transduction 
efficiency.  Cells expressing eGFP were observed by fluorescent microscopy.  
For in vitro analyses, BAL and peritoneal macrophages were transduced in 
culture with Lenti-PPARγ or Lenti-eGFP for 24 hours in Opti-MEM (Invitrogen) 
media and then incubated 24 hours in complete DMEM media (Invitrogen) prior 
to collection.   
 
RNA purification and analysis.  Total RNA was extracted from cells by RNeasy 
protocol (Qiagen, Valencia, CA).  Expression of mRNA was determined by real time 
RT-PCR using the ABI Prism 7300 Detection System (TaqMan, Applied Biosystems, 
Foster City, CA) according to the manufacturer’s instructions.  RNA specimens were 
analyzed in duplicate using primer/probe sets for mouse PPARγ (Mm0040945) and 
human PPARγ (Hs00234592) (ABI) as previously described (51).  Primer/probe 
sequences for eGFP have been described (123).  Threshold cycle (CT) values for 
genes of interest were normalized to a housekeeping gene [glyceraldehyde 3 
phosphate dehydrogenase, (GAPDH)] and used to calculate the relative quantity of 
mRNA expression.  Data were expressed as a fold change in mRNA expression 
relative to control values (98). 
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Protein analysis.  Whole cell lysates were prepared using a modified Nonidet P-
40 lysis buffer as described previously (51).  10% SDS-PAGE gels were loaded 
based on equal protein obtained by the bicinchoninic acid assay (Pierce, 
Rockford, IL).  Primary antibody to PPARγ (H-100, Santa Cruz Biotechnology, 
Santa Cruz, CA) was diluted to 1:000 and blots were visualized by 
chemiluminescence.  
 
Statistical analysis.  Data were analyzed by Student’s t-test using Prism software 
(GraphPad, Inc., San Diego, CA).  Significance was defined as p ≤ 0.05.   
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Results 
 
Lenti-PPARγ mediates stable expression of PPARγ in human and mouse 
cell lines.  Preliminary experiments demonstrating the stable expression of 
eGFP and PPARγ were carried out on HeLa and MH-S cell lines.  HeLa and MH-
S cells were transduced with Lenti-eGFP.  After 72 hours, cells were challenged 
with blasticidin (10 µg/uL).  After several passages, cells were collected for 
analysis.  HeLa cells exhibited eGFP positive cells (Figure 3.3A).  Experiments 
testing the Lenti-PPARγ virus were carried out in a similar manner.  Neither HeLa 
nor MH-S cells express detectable amounts of PPARγ.  RT-PCR analysis of 
HeLa and MH-S cells transduced with Lenti-PPARγ, however, exhibit increased 
expression of PPARγ mRNA (Figure 3.3B).  Transduction with serial dilutions of 
Lenti-PPARγ virus resulted in up-regulation of PPARγ protein in HeLa cells 
(Figure 3.3C). 
 
Lenti-PPARγ mediates efficient up-regulation of PPARγ in primary murine 
macrophages.  To determine the transduction efficiency of the Lenti-PPARγ 
virus on primary cells, we harvested peritoneal macrophages from wild type and 
GM-CSF KO mice which do not express detectable levels of PPARγ and treated 
the cells with Lenti-PPARγ in vitro.  Analysis by RT-PCR demonstrated increased 
levels of PPARγ in a dose-dependent manner in wild type and GM-CSF KO cells  
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Figure 3.3 Lenti-PPARγ mediates expression of PPARγ in human and 
mouse cell lines.  (A) HeLa cells expressed eGFP after transduction with Lenti-
eGFP.  (B) RT-PCR analysis of HeLa and MH-S cell lines transduced with Lenti-
PPARγ exhibited increased expression of PPARγ mRNA.  (C) Transduction with 
serial dilutions of Lenti-PPARγ virus resulted in the up-regulation of PPARγ 
protein in HeLa cells.  
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compared to non-transduced controls (Figure 3.4A-B).  Further, we transduced 
alveolar macrophages of GM-CSF KO and noted increased expression of PPARγ 
mRNA (Figure 3.4C).  Transduction with control Lenti-eGFP virus did not result in 
increases in PPARγ mRNA in any experiment.  These results demonstrated 
efficient up-regulation of PPARγ in peritoneal macrophages that do not 
constitutively express PPARγ and alveolar macrophages deficient in PPARγ. 
 
Lentivirus mediates up-regulation of eGFP and PPARγ in alveolar 
macrophages from healthy human controls.  In order to evaluate the 
Lentivirus expression system in primary human macrophages, we transduced 
alveolar macrophages from healthy controls with increasing titers of Lenti-eGFP 
and measured eGFP mRNA by RT-PCR (Figure 3.5A).  Transduction efficiency 
was also determined by counting eGFP-positive cells [data previously published 
(51)].  Additionally, a preliminary experiment demonstrated a 60-fold increase in 
PPARγ mRNA expression in alveolar macrophages from a healthy individual 
upon transduction with Lenti-PPARγ (Figure 3.5B).  Taken together, these results 
provide evidence that Lenti-PPARγ is an effective investigative tool to study the 
up-regulation of PPARγ in primary alveolar macrophages. 
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Figure 3.4  Lenti-PPARγ mediates efficient up-regulation of PPARγ in 
primary murine macrophages.  (A) RT-PCR analysis demonstrated dose-
dependent up-regulation of PPARγ mRNA in WT and (B) GM-CSF KO peritoneal 
macrophages treated with Lenti-PPARγ virus compared to non-transduced cells 
(0 ng/mL p24).  Expression of PPARγ mRNA in macrophages treated with control 
virus (Lenti-eGFP) was not different from non-treated cells.  (C) Up-regulation of 
PPARγ was also detected by RT-PCR in GM-CSF alveolar macrophages upon 
treatment with Lenti-PPARγ (25 ng/mL p24).   
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Figure 3.5 Lentivirus mediates up-regulation of eGFP and PPARγ in alveolar 
macrophages from healthy human controls.  (A) Human alveolar 
macrophages transduced with Lenti-eGFP for 24 hours up-regulated eGFP 
mRNA in a dose-dependent manner.  (B) Alveolar macrophages from a healthy 
control exhibited increased PPARγ mRNA expression upon transduction with 
Lenti-PPARγ. 
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Discussion 
 
 
PPARγ is deficient in the alveolar macrophages of PAP patients and GM-
CSF KO mice (6,51).  Previous studies from our laboratory have implicated 
PPARγ in the promotion of surfactant catabolism in alveolar macrophages 
(unpublished data).  PPARγ regulates several genes involved in the transcription 
and transport of lipids in macrophages.  In order to investigate our hypothesis 
that the up-regulation of PPARγ will increase surfactant catabolism and reduce 
the presence of lipid-engorged alveolar macrophages in the lung, we required an 
efficient system to up-regulate PPARγ in primary macrophages. 
Lentivirus vectors are capable of delivering and expressing a gene of 
interest without being disruptive to the host cell (120).  Secondly, the Lentivirus 
expression system is an advantageous therapeutic gene delivery system and has 
the potential for delivery of genetic material in vivo.  In the present study, we 
utilized the Lentivirus system to transduce primary murine and human alveolar 
macrophages in vitro.   
In initial experiments, the Lenti-eGFP virus was used to measure 
transduction efficiency.  Additionally, macrophages transduced with Lenti-eGFP 
were used as a control in RT-PCR analysis as these samples did not exhibit 
significant changes in PPARγ mRNA compared to non-transduced cells.  Thus, 
the up-regulation in PPARγ is due to the specific Lenti-PPARγ construct and not 
produced in response to foreign DNA or macrophage activation upon the 
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introduction of virus.  Additional preliminary work entailed determining optimal 
Lentivirus transduction concentrations.  Dose responses ranging from 2.5-25 
ng/mL p24 were carried out on cultured peritoneal macrophages from wild type 
and GM-CSF KO mice.  Alveolar macrophages from GM-CSF KO mice were 
transduced with 25 ng/mL p24.  We next investigated the use of the Lentivirus 
constructs on alveolar macrophages from healthy volunteers.  All doses induced 
transcription of PPARγ supporting the efficiency of the Lentivirus expression 
system.   
These experiments demonstrate successful up-regulation of the proteins 
of interest, eGFP and PPARγ, and provide a foundation to pursue in vivo 
replacement of PPARγ in GM-CSF KO alveolar macrophages using Lenti-
PPARγ.  Unlike adenoviral vectors which offer poor efficiency and transient 
expression of the delivered gene, Lenti-PPARγ provides efficient up-regulation of 
PPARγ and may used in a variety of experiments to investigate the transcriptional 
regulation of PPARγ.  This system provides a reliable approach to study the role 
of PPARγ gene expression in surfactant catabolism and homeostasis in alveolar 
macrophages.  Understanding surfactant homeostasis is fundamental to the 
treatment of human pulmonary disease.   
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Abstract 
 
Peroxisome proliferator-activated receptor-gamma (PPARγ) is a nuclear 
transcription factor involved in lipid metabolism that is constitutively expressed in 
the alveolar macrophages of healthy individuals.  While the mechanism remains 
unclear, PPARγ has recently been implicated in the catabolism of surfactant by 
alveolar macrophages, specifically the cholesterol component of surfactant.  
Studies from other tissue macrophages have shown that PPARγ transcriptionally 
regulates genes involved in cholesterol metabolism.  PPARγ promotes the 
expression of the liver X receptor-alpha (LXRα) and ATP-binding cassette G1 
(ABCG1) which are involved in cholesterol efflux and CD36 which is involved in 
the uptake of cholesterol.  We have recently shown that macrophage-specific 
PPARγ knockout (PPARγ KO) mice accumulate cholesterol-laden alveolar 
macrophages that exhibit decreased expression of LXRα and ABCG1 and 
reduced cholesterol efflux.  We hypothesized that in addition to dysregulated 
cholesterol efflux, cholesterol biosynthesis and uptake genes were also 
dysregulated and that replacement of PPARγ would induce expression of these 
genes.  To investigate this hypothesis, we have utilized a Lentivirus expression 
system (Lenti-PPARγ) to restore PPARγ expression in the alveolar macrophages 
of PPARγ KO mice.   Our results show that the alveolar macrophages of PPARγ 
KO mice have decreased expression of key cholesterol biosynthesis genes and 
increased expression of cholesterol receptors CD36 and scavenger receptor A-I 
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(SRA-I).  The replacement of PPARγ induced transcription of LXRα and ABCG1; 
(2) corrected suppressed expression of cholesterol biosynthesis genes; and (3) 
enhanced the expression of CD36. These results suggest that PPARγ regulates 
cholesterol metabolism in alveolar macrophages.  
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Introduction 
 
 
Pulmonary alveolar proteinosis (PAP) is an autoimmune lung disease 
characterized by the accumulation of surfactant (1).  Pulmonary surfactant is 
comprised of 90% lipid, 10% protein, and less than 1% carbohydrate. The lipid 
component is comprised of phospholipids and neutral lipids, cholesterol being the 
major neutral lipid (93).  Alveolar macrophages catabolize and recycle 
cholesterol from surfactant.  However, the alveolar macrophages of PAP patients 
do not catabolize surfactant sufficiently and become engorged with lipid 
(25,26,28,50).  It has been shown that cholesterol levels are increased in the 
lungs of PAP patients (47).  Combined with the presence of foam cells in the 
lungs of patients, these results provided evidence that homeostasis of cholesterol 
catabolism may be disrupted in PAP.  Interestingly, the contribution of impaired 
cholesterol catabolism to the overall disruption of surfactant catabolism in the 
pathogenesis of PAP has not been specifically addressed.   
Our laboratory was the first to determine that the alveolar macrophages of 
PAP patients were deficient in the nuclear transcription factor peroxisome 
proliferator-activated receptor-gamma (PPARγ) (6,51).  Although the role of 
PPARγ in the lung is relatively unexplored, PPARγ has been implicated as a 
critical mediator in cholesterol metabolism in various tissue macrophages.  Given 
the amount of cholesterol present in lung surfactant, PPARγ may hold particular 
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importance in promotion of cholesterol catabolism in alveolar macrophages and 
deficient cholesterol catabolism could impair the catabolism of surfactant overall.   
Studies on other tissue macrophages have shown that PPARγ regulates 
many genes involved in cholesterol transport (influx and efflux) and metabolism. 
PPARγ transcriptionally promotes the sterol-sensing nuclear transcription factor 
liver X receptor-alpha (LXRα) and cholesterol transporter ATP-binding cassette 
G1 (ABCG1) (51,77,94). The PPARγ-LXR cascade is critical to maintaining 
cholesterol efflux in macrophages (85).  CYP27A1 is an important enzyme that 
converts cholesterol into LXR ligands thereby promoting cholesterol transport 
from extrahepatic macrophages (112).  Additionally, alveolar macrophages have 
been shown to readily secrete the more polar hydroxycholesterol produced by 
CYP27A1 in response to cholesterol-loading (124,125).   
While deficiencies in cholesterol efflux could lead to cholesterol 
accumulation (75), the uptake of cholesterol via scavenger receptors has also 
been strongly associated with the accumulation of cholesterol (126,127).  
Scavenger receptors are up-regulated in the presence of substrate yielding 
macrophages with the unique capacity for cholesterol uptake regardless of 
intracellular cholesterol levels.  The scavenger receptors CD36 and scavenger 
receptor A-I (SRA-I) internalize cholesterol bound to oxidized (ox)-LDL [reviewed 
by Glass and Witztum (74)].  Macrophages from mice lacking CD36 and SRA-I 
exhibit a 90% reduction in ox-LDL uptake (126).  Although scavenger receptor-
mediated cholesterol uptake is complex and is not fully understood, it is known to 
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be regulated in part by PPARγ: CD36 is directly up-regulated by PPARγ (61) 
while SRA-I is negatively regulated by PPARγ (60).   
PPARγ regulates both the cholesterol influx (CD36 and SRA-I) and efflux 
genes (LXRα and ABCG1) and therefore influences the level of intracellular 
cholesterol present in macrophages.  In turn, cholesterol levels regulate the de 
novo synthesis of cholesterol.  In response to limited cholesterol, the nuclear 
transcription factor sterol response element-binding protein 2 (SREBP2) 
promotes cholesterol synthesis and uptake through the up-regulation of 3-
hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and low-density 
lipoprotein receptor (LDL-R) [reviewed by Goldstein, et al. (67)].  Alternatively, 
intracellular cholesterol and oxysterols negatively regulate cholesterol synthesis 
in part by reduced transcriptional activity of SREBP2. 
To investigate PPARγ and the promotion of cholesterol catabolism in 
alveolar macrophages, we have utilized macrophage-specific PPARγ knockout 
(PPARγ KO) mice which develop a PAP-like lung pathology with the 
accumulation of cholesterol and foamy, cholesterol-laden alveolar macrophages 
(unpublished data).  The alveolar macrophages of PPARγ KO mice exhibit 
decreased expression of LXRα and ABCG1 and reduced cholesterol efflux.   
These results suggest PPARγ is a key mediator of cholesterol catabolism 
in alveolar macrophages.  Thus, we hypothesized that in addition to dysregulated 
cholesterol efflux genes, the expression of cholesterol synthesis and influx genes 
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were also dysregulated in the alveolar macrophages of PPARγ KO mice.  To test 
this hypothesis we investigated the expression cholesterol metabolism genes 
and the effects of in vivo replacement of PPARγ using a Lentivirus expression 
system (Lenti-PPARγ).  
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Materials and Methods 
 
Mice. Animal studies were conducted in conformity with Public Health Service 
policy on the humane care and use of laboratory animals and were approved by 
the Institutional Animal Care Committee.  C57Bl/6 wild type mice were obtained 
from Jackson Laboratory (Bar Harbor, ME).  Macrophage-specific PPARγ KO 
mice have been previously described (96).  BAL cells were obtained as 
described earlier from 8–12 week old PPARγ KO mice and age- and gender-
matched wild type C57Bl/6 controls (96). For experiments, a minimum of 4 
individual PPARγ KO mice were used except where indicated.  For wild type 
mice, a minimum of 3 sets of pooled cells from 3-5 mice were used in all 
experiments.  Briefly, the thoracic cavity was opened and the lungs were 
exposed. After cannulating the trachea, a tube was inserted and BAL was carried 
out with warmed (37°C) PBS in 1 mL aliquots. Cell via bility was measured by 
trypan blue exclusion.  BAL cell differentials from all animals used in the 
experiments were stained with a Wright-Giemsa stain and revealed >90% 
macrophages.   
 
Lentivirus plasmid and instillation. A self-inactivating Lentivirus expression 
vector containing cDNA corresponding to the human PPARγ (Lenti-PPARγ) was 
cloned into the multiple cloning sites downstream of a CMV promoter using 
standard techniques as described (96,121).  A Lentivirus expressing the 
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enhanced Green Fluorescent Protein (Lenti-eGFP) was obtained using a similar 
protocol and was utilized as a control.  For experiments utilizing Lenti-eGFP and 
Lenti-PPARγ, mice were intra-tracheally instilled 30 days prior to BAL, as 
described previously (96).  
 
RNA purification and analysis.  Total RNA was extracted from the cells by the 
RNeasy protocol (Qiagen, Valencia, CA).  Expression of mRNA was determined 
by real-time RT-PCR analysis using the ABI Prism 7300 Detection System 
(TaqMan; Applied Biosystems, Foster City, CA) according to the manufacturer's 
instructions.  RNA specimens were analyzed in duplicate using primer sets for 
mouse ABCA1 (Mm00442646), ABCG1 (Mm00437390), CD36 (Mm00432403), 
HMGCR (Mm01282494), LDL-R (Mm00440169), LXRα (Mm00443454), LXRβ 
(Mm00437262), SRA-I (Mm00446214), and SREBP2 (Mm01306300) (Applied 
Biosystems).  Threshold cycle values for genes of interest were normalized to a 
housekeeping gene (GAPDH, 4352339E) (Applied Biosystems) and used to 
calculate the relative quantity of mRNA expression in PPARγ KO samples 
compared with wild type murine controls.  For the Lentivirus experiments, Lenti-
eGFP samples were used as the controls for Lenti-PPARγ samples.  Data are 
expressed as fold change in mRNA expression relative to control values (98).  
 
Statistical analysis.  Data were analyzed by Student's t-test using Prism 
software (GraphPad, Inc., San Diego, CA). Significance was defined as p ≤ 0.05. 
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Results and Discussion 
 
Cholesterol metabolism genes are dysregulated in PPARγ KO alveolar 
macrophages.  We have previously shown that the alveolar macrophages of 
PPARγ KO mice exhibit reduced cholesterol efflux and are loaded with 
cholesterol (unpublished data).  The lungs of PPARγ KO mice also have elevated 
levels of cholesterol.  Therefore, we investigated the expression of cholesterol 
metabolism and biosynthesis genes that are regulated by intracellular and 
extracellular cholesterol in the alveolar macrophages of PPARγ KO mice.   
RT-PCR analysis of SREBP2 and downstream targets HMGCR and LDL-
R in the alveolar macrophages of PPARγ KO mice demonstrated that the 
expression of SREBP2, HMGCR, and LDL-R was significantly decreased (1.8-
fold, 1.5-fold, and 1.9-fold respectively) compared to wild type (Figure 4.1A).  
Alternatively, the expression of scavenger receptors CD36 and SRA-I which are 
positively regulated by extracellular cholesterol content, specifically cholesterol 
bound to ox-LDL (74), was up-regulated 1.5-fold and 10.1-fold, respectively 
(Figure 4.1B).   
While the regulation of cholesterol synthesis genes is complex, cholesterol 
has been shown to negatively regulate cholesterol synthesis at the transcriptional 
level (128).  Wang, et al. demonstrated that the accumulation of free cholesterol 
in ABCG1-deficient macrophages inhibited the expression of HMGCR and LDL-R 
(129).  THP1-derived macrophages loaded with ox-LDL displayed reduced 
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Figure 4.1  Cholesterol metabolism genes are dysregulated in PPARγ KO 
alveolar macrophages.  (A) RT-PCR analysis demonstrated that genes involved 
in the biosynthesis and uptake of cholesterol SREBP2, HMGCR, and LDL-R are 
down-regulated in the PPARγ KO compared to wild type.  (B)  Expression of 
scavenger receptors CD36 and SRA-I are increased in the PPARγ KO compared 
to wild type.   
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HMGCR mRNA (130).  Moreover, incubation of murine macrophages with 
modified-LDL decreased HMGCR enzymatic activity (131).  Decreased 
expression of cholesterol synthesis genes in the cholesterol-laden alveolar 
macrophages of PPARγ KO mice indicates that the suppression of cholesterol 
synthesis is intact, in contrast to sterol-insensitive cells which continue to 
produce cholesterol when loaded (132).   
While reduced cholesterol efflux, such as that observed in the PPARγ KO, 
can contribute to cholesterol-overload, enhanced ox-LDL uptake via scavenger 
receptors is also strongly linked to the accumulation of cholesterol.  PPARγ has 
been implicated in the regulation of cholesterol uptake by CD36 and SRA-I.  
Exposure of THP-1 macrophages with ox-LDL induces expression of PPARγ, 
CD36, and SRA-I (58).  While PPARγ directly promotes expression of CD36 (61), 
SRA-I can be negatively regulated by PPARγ and independently of PPARγ by the 
presence of ox-LDL (105,106).  In the present study, PPARγ KO alveolar 
macrophages exhibited highly up-regulated SRA-I.  Therefore, elevated 
expression of SRA-I may reflect the combination of substrate availability and the 
absence of PPARγ.   
 In addition to cholesterol, we have also shown that other surfactant lipids 
accumulate in the alveolar macrophages of PPARγ KO mice (unpublished data).  
Analysis of phospholipid, fatty acid, and triglyceride synthesis genes (lipin1, fatty 
acid synthase, SREBP1c, diacylglycerol acyltransferase, and glycerol-3-
phosphate acyltransferase) by RT-PCR revealed no differences in expression 
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compared to wild type mice (data not shown).  This data indicates (1) it is unlikely 
that the intracellular accumulation of lipids is due to de novo synthesis, and (2) 
PPARγ is particularly critical to the regulation of cholesterol. 
We demonstrate in the present study that the cholesterol synthesis 
pathway is suppressed in PPARγ KO alveolar macrophages, as evidenced by 
decreased expression of SREBP2, HMGCR, and LDL-R while the uptake of ox-
LDL may be enhanced given that the expression of CD36 and SRA-I is 
increased.  These results demonstrate that both systems are responsive to the 
accumulation of cholesterol in the lungs and alveolar macrophages of PPARγ KO 
mice.    
 
Up-regulation of PPARγ in vivo promotes the expression of cholesterol 
efflux genes.  We have determined that the expression of PPARγ-regulated 
genes LXRα and ABCG1 was reduced in the alveolar macrophages of PPARγ 
KO mice (unpublished data).  Additionally, we demonstrated that LXRβ and 
CYP27A1 were up-regulated.  As a continuation of this work, we investigated the 
expression of these genes upon up-regulation of PPARγ in vivo.  RT-PCR 
analysis demonstrated ABCG1 and LXRα mRNA was up-regulated (1.8-fold and 
1.6-fold, respectively) in PPARγ KO mice instilled with Lenti-PPARγ compared to 
mice instilled with Lenti-eGFP (Figure 4.2A).  LXRβ and CYP27A1 were also up- 
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Figure 4.2 Up-regulation of PPARγ in vivo promotes the expression of 
cholesterol efflux genes.  (A)  RT-PCR analysis revealed ABCG1 and LXRα 
expression in the alveolar macrophages of PPARγ KO mice instilled with Lenti-
PPARγ were up-regulated compared to controls. (B)  The expression of LXRβ 
and CYP27A1 was increased in Lenti-PPARγ treated animals (n=3) compared to 
Lenti-eGFP controls. 
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regulated 4.9-fold and 3.5-fold, respectively, in PPARγ KO instilled with Lenti-
PPARγ (Figure 4.2B).   
While the restoration of ABCG1 mRNA confirms previous results directly 
linking PPARγ to ABCG1 expression (51), perhaps the most significant finding in 
this report is the induction of LXRα in treated PPARγ KO mice.  Peritoneal 
macrophages from PPARγ KO mice have been shown to exhibit decreased 
expression of LXRα which did not increase upon treatment with ligand due to the 
absence of PPARγ (100).  Consistent with findings from other tissue 
macrophages in which upstream PPARγ signaling was essential to the promotion 
of cholesterol efflux by LXRα (77), PPARγ appears to be essential to the 
promotion of cholesterol efflux by LXRα in alveolar macrophages.  These results 
indicate that PPARγ is a key regulator of cholesterol efflux. 
Increased expression of CYP27A1 in the alveolar macrophages of PPARγ 
KO mice instilled with Lenti-PPARγ may have contributed to increased LXRβ 
expression through the production of LXR ligand (112).  Llaverias, et al. have 
reported that the loading of macrophages with cholesterol results in increased 
CYP27A1 expression (133).  While LXRβ has been shown to be regulated 
independently of PPARγ (77), CYP27A1 can be regulated by PPARγ.  At least 
two reports have demonstrated that the transcription of CYP27A1 is inducible by 
PPARγ ligands, independent of LXR or cellular cholesterol content (134,135).  
Therefore, increased expression of CYP27A1 in untreated PPARγ KO may result 
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from intracellular cholesterol content, while in treated mice PPARγ may directly 
contribute to the expression of CYP27A1 to promote the removal of cholesterol 
from alveolar macrophages. 
Taken together, these data indicate that the replacement of PPARγ in 
cholesterol-laden macrophages promotes the expression of cholesterol efflux 
through transcription of LXRα, ABCG1, and CYP27A1. 
 
Up-regulation of PPARγ in vivo increases expression of cholesterol 
metabolism genes.  In contrast to decreased expression of cholesterol 
synthesis genes in PPARγ KO alveolar macrophages, restoration of PPARγ in 
vivo resulted in the up-regulation of SREBP2, HMGCR, and LDL-R mRNA 
compared to Lenti-eGFP controls (1.7-fold, 1.9-fold, and 1.7-fold, respectively) 
(Figure 4.3A).  Replacement of PPARγ also resulted in increased expression of 
CD36 (2.1-fold) while no significant changes in SRA-I expression were observed 
(Figure 4.3B).   
 Overexpression of SREBP-2 has been shown to increase the mRNA 
expression of all cholesterol synthesis enzymes, with the highest induction of 
HMGCR (136).  Although predominantly recognized to be transcriptionally 
regulated by SREBP2 (137), PPARγ has been also implicated in the transcription 
of HMGCR.  Both the mRNA and enzyme activity of HMGCR was increased 
THP-1 cells treated with PPARγ agonists (138).  Increased expression of 
cholesterol biosynthesis genes SREBP-2 and HMGCR upon up-regulation of 
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Figure 4.3 Up-regulation of PPARγ in vivo increases expression of 
cholesterol metabolism genes.  (A)  RT-PCR analysis of alveolar macrophages 
revealed increased expression of SREBP2, HMGCR, and LDL-R in PPARγ KO 
instilled with Lenti-PPARγ (n=3) compared to controls.  (B) CD36 mRNA was up-
regulated after instillation with Lenti-PPARγ compared to Lenti-eGFP controls.  
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PPARγ suggests an indirect relationship between PPARγ and the synthesis of 
cholesterol, probably mediated by intracellular sterol levels.  These results 
provide evidence that the up-regulation of PPARγ and downstream genes 
involved in cholesterol efflux including LXRα, ABCG1, and CYP27A1 relieved 
inhibition of the cholesterol biosynthesis genes (Figure 4.4).   
The induction of CD36 mRNA upon the restoration of PPARγ is consistent 
with previous studies demonstrating that CD36 is transcriptionally promoted by 
PPARγ (58).  Given that PPARγ can negatively regulate SRA-I (105,106), it was 
somewhat unexpected to find that the expression of SRA-I was unchanged in 
PPARγ KO mice upon up-regulation of PPARγ.  However, ox-LDL can induce 
expression of SRA-I independently of PPARγ (139).  Our results suggest that 
increased expression of SRA-I occurs in the absence of PPARγ, and that 
continued expression SRA-I after PPARγ replacement may be attributed to 
substrate availability.  Further, elevated expression of CD36 and SRA-I suggest 
that the uptake of cholesterol is enhanced in the alveolar macrophages of PPARγ 
KO mice.  
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Figure 4.4 Hypothetical pathway by which PPARγ regulates cholesterol 
influx, efflux, and biosynthesis in alveolar macrophages.  PPARγ directly 
promotes transcription of cholesterol influx and efflux genes which determine the 
intracellular cholesterol level.  In turn, cholesterol levels regulate the de novo 
synthesis of cholesterol.  
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Conclusions 
 
Alveolar macrophages of PPARγ KO mice exhibit decreased expression 
cholesterol influx, efflux, and biosynthesis genes.  The replacement of PPARγ in 
vivo increased expression of cholesterol efflux genes ABCG1 and LXRα, 
cholesterol biosynthesis genes SREBP2 and HMGCR, and receptors LDL-R and 
CD36.  These results suggest that PPARγ regulates cholesterol metabolism in 
alveolar macrophages and promotes the catabolism and transport of cholesterol 
in the lung.  Our findings provide evidence that the catabolism of cholesterol 
affects the catabolism of surfactant overall and may have implications in the 
study of PPARγ and human lung diseases associated with the accumulation of 
surfactant. 
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Abstract 
 
Pulmonary alveolar proteinosis (PAP) is a lung disease characterized by 
neutralizing auto-antibodies to granulocyte-macrophage colony-stimulating factor 
(GM-CSF).  The loss of functional GM-CSF results in the filling of alveolar spaces 
and alveolar macrophages of the lungs with surfactant.  The nuclear transcription 
factor peroxisome proliferator-activated receptor-gamma (PPARγ), a key 
regulator of lipid metabolism, is constitutively expressed in the alveolar 
macrophages of healthy individuals and is up-regulated by GM-CSF.  We have 
previously demonstrated decreased levels of PPARγ and ATP-binding cassette 
transporter G1 (ABCG1) in the alveolar macrophages from both PAP patients 
and GM-CSF knockout (GM-CSF KO) mice, suggesting the involvement of 
PPARγ and ABCG1 in surfactant catabolism.  We hypothesized that up-
regulation of PPARγ would lead to an increase in ABCG1 and decrease lipid 
accumulation in alveolar macrophages.  The up-regulation of PPARγ was 
achieved using a Lentivirus expression system in vivo.  GM-CSF KO mice 
received instillation of Lentivirus (Lenti)-PPARγ or control Lenti-eGFP (enhanced 
Green Fluorescence Protein) via the intra-tracheal route.  Alveolar macrophages 
were harvested 10 and 30 days post-instillation.  Fluorescence microscopy 
indicated that 79 and 54% of alveolar macrophages instilled with Lenti-eGFP 
contained eGFP at 10 and 30 days post-instillation, respectively.  We 
demonstrated significant increases in PPARγ and ABCG1 gene expression in 
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alveolar macrophages of mice instilled with Lenti-PPARγ, while PPARγ and 
ABCG1 levels remained unchanged in control groups instilled with Lenti-eGFP or 
PBS.  Oil Red O positivity was reduced within the alveolar macrophages of mice 
treated with Lenti-PPARγ at 10 days post-instillation.  Finally, we measured 
increased ABCG1-mediated cholesterol efflux in alveolar macrophages from 
Lenti-PPARγ treated mice at 10 days.  Results with Lenti-PPARγ instillations 
demonstrate: (1) efficient in vivo transduction of alveolar macrophages; (2) up-
regulation of ABCG1; (3) a reduction in macrophage lipid accumulation; and (4) 
increased ABCG1-mediated cholesterol efflux.  These studies suggest that the 
expression PPARγ and ABCG1 in alveolar macrophages promotes the 
catabolism of surfactant. 
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Introduction 
 
Pulmonary alveolar proteinosis (PAP) is a rare autoimmune disease 
characterized by neutralizing auto-antibodies to granulocyte-macrophage colony-
stimulating factor (GM-CSF) (1,91). Genetically engineered mice which are 
homozygous for a disrupted GM-CSF gene develop a PAP-like lung disease with 
the accumulation of excess surfactant (29,30,140).  These studies have revealed 
a previously unknown role for GM-CSF in normal lung homeostasis, as 
pathogenesis in PAP patients and mouse models are confined to the lung.   
The alveolar macrophages in PAP patients and GM-CSF knockout (GM-
CSF KO) mice are foamy and laden with lipid, as evidenced by positive Oil Red 
O staining (50,51).  The accumulation of surfactant has been linked decreased 
clearance by the alveolar macrophages of PAP and GM-CSF KO rather than 
increased production of surfactant (25,26,28).  Interestingly, GM-CSF up-
regulates the nuclear transcription factor peroxisome proliferator-activated 
receptor-gamma (PPARγ) expression in alveolar macrophages suggesting the 
involvement of PPARγ in surfactant clearance (6).  PPARγ is constitutively 
expressed in the alveolar macrophages of healthy individuals but deficient in the 
alveolar macrophages of PAP patients and GM-CSF KO mice (6).   
A critical role for PPARγ has been reported in regulation of genes involved 
in lipid metabolism as well as in inflammation (141).  PPARγ is one of the key 
proteins involved in regulating macrophage cholesterol efflux and this regulation 
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may involve expression of the ATP-binding cassette (ABC) transporters ABCG1 
and ABCA1 (58,61,77,100,142,143).  Our laboratory has recently shown that the 
expression of ABCG1 is decreased in the alveolar macrophages of PAP patients 
and GM-CSF KO mice (51).  The studies of PAP and GM-CSF KO mice have 
shown that GM-CSF is a critical mediator of surfactant clearance.  We 
hypothesized that GM-CSF mediates surfactant catabolism in alveolar 
macrophages through a PPARγ-ABCG1 pathway and that up-regulation of 
PPARγ in would lead to an increase in ABCG1 and decrease the lipid 
accumulating in the alveolar macrophages of GM-CSF KO mice.  To address this 
hypothesis we utilized a Lentivirus expression system in vivo to up-regulate 
PPARγ. 
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Materials and Methods 
 
Mice.  Animal studies were conducted in conformity with Public Health Service 
(PHS) Policy on humane care and use of laboratory animals and were approved 
by the institutional animal care committee.  The GM-CSF KO mice were 
generated by Dr. Glenn Dranoff (29).  The mice have been backcrossed eight 
generations to C57Bl/6.   
 
Bronchoalveolar lavage (BAL).  Post lenti-instillation (10 or 30 days) 5-7 
animals per group were lavaged.  Mice received ketamine (90 mg/kg) and 
xylazine (10 mg/kg) intraperitoneally.  The thoracic cavity was opened and the 
lungs were exposed.  After cannulating the trachea a tube was inserted and 
bronchoalveolar lavage was carried out with warmed (37oC) PBS in 1ml aliquots.  
Cytospins of BAL cells were stained with a modified Wright–Giemsa stain for 
differentials or Oil Red O stain to detect intracellular neutral lipids, and 
counterstained with Gill’s hematoxylin stain.  Viability was >95% as determined 
by trypan blue for all cell preparations. 
 
Lentivirus construction and transduction.  A self-inactivating Lentivirus 
expression vector that was previously utilized in the generation of a stable cell 
line expressing the human parainfluenza virus type 3 C protein was used for 
these experiments (51,121).  cDNA corresponding to the human PPARγ 
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sequence was cloned into the multiple cloning sites downstream of a CMV 
promoter using standard techniques as described (121).  The recombinant 
Lentiviral plasmid thus obtained was transfected into 293FT cells along with 
plasmids encoding the gag, pol and rev genes and a plasmid possessing the 
vesicular stomatitis glycoprotein (G) using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA).  At 72 hrs post transfection, cell culture supernatant containing 
the Lentivirus-PPARγ (Lenti-PPARγ) was collected and then purified by 
centrifugation at 27,000 rpm at 40C for 3.5 hrs.  The Lenti-PPARγ virus pellet was 
resuspended in PBS and aliquots of 100µl were stored at -700C.  The 
concentration of Lenti-PPARγ virus was determined by a p24 ELISA (Cell 
Biolabs, San Diego, CA).  A Lentivirus expressing the enhanced Green 
Fluorescent Protein (Lenti-eGFP) was obtained using a similar protocol and was 
utilized as a control in experiments for the determination of transduction 
efficiency.  For in vivo analyses, GM-CSF KO received 50 ng/mL p24 of Lenti-
PPARγ in 50 uL of PBS, Lenti-eGFP or PBS alone (sham) by intra-tracheal 
instillation.   
 
RNA purification and analysis.  Total RNA was extracted from cells by RNeasy 
protocol (Qiagen, Valencia, CA).  Expression of mRNA was determined by real 
time RT-PCR using the ABI Prism 7300 Detection System (TaqMan, Applied 
Biosystems, Foster City, CA) according to the manufacturer’s instructions.  RNA 
specimens were analyzed in duplicate using primer/probe sets for mouse PPARγ, 
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ABCA1 and ABCG1 (ABI) as previously described (51).  Threshold cycle (CT) 
values for genes of interest were normalized to a housekeeping gene 
[glyceraldehyde 3 phosphate dehydrogenase, (GAPDH)] and used to calculate 
the relative quantity of mRNA expression.  Data were expressed as a fold 
change in mRNA expression relative to control values (98). 
 
Cholesterol efflux assay.  BAL cells were plated in 48 well cell culture plates 
(3.5x105 per well) in complete media and maintained at 37°C and 5% CO2.  Cells 
were incubated for 24 hours in 2 µCi/mL [1,2-3H(N)]-cholesterol (NEN, Perkin 
Elmer, Waltham, MA), washed and equilibrated in serum free media for 24 hours.  
Cells were then treated with no acceptors or in the presence of high density 
lipoprotein (HDL) (25µg/uL) (Intracel, Frederick, MD) for an additional 24 hours.  
Supernatants were harvested and cell debris removed by a 5 minute 
centrifugation at 1800 rpm. Cells were washed with 1XPBS and dissolved in 0.2 
M NaOH with 0.1% SDS for 1 hour at room temperature. Aliquots of cell lysates 
and supernatants were counted by liquid scintillation.  Cholesterol efflux was 
expressed as the percentage of radioactivity in the supernatant divided by the 
total radioactivity of the cells and supernatant.  Each assay was run in duplicate.   
 
Cholesterol content analysis. Cholesterol was measured in BAL fluid using the 
Amplex Red Cholesterol Assay (Molecular Probes, Invitrogen, Eugene, OR) 
according to the manufacturer’s protocol.  Aliquots of cell-free BAL fluid were 
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assayed in serial dilution in 96-well plates.  Data is expressed as µg of 
cholesterol per mL of BAL fluid. 
 
Statistical analysis.  Data were analyzed by Student’s t-test using Prism 
software (GraphPad, Inc., San Diego, CA).  Significance was defined as p ≤ 0.05.   
119 
Results 
 
Lentivirus efficiently transduces alveolar macrophages in vivo.  To monitor 
the transduction efficiency of Lentivirus vectors in alveolar macrophages of GM-
CSF KO mice, we utilized Lenti-eGFP and quantified the number of eGFP 
positive alveolar macrophages (Figure 5.1).  The transduction efficiency was 
79% at 10 days and 54% at 30 days.  Based on these results, the remaining 
experiments were carried only to 10 days post-instillation.  
 
PPARγ and cholesterol transporters ABCG1 and ABCA1 are up-regulated.  
To evaluate the effect of Lenti-PPARγ transduction on alveolar macrophages, 
RNA was extracted from freshly isolated BAL cells at 10 days post-instillation and 
compared to sham treated GM-CSF KO mice (Figure 5.2).  PPARγ mRNA was 
up-regulated 2-fold.  We next evaluated the effect of Lenti-PPARγ on the PPARγ-
regulated transporters ABCG1 and ABCA1, and determined that their mRNA 
expression was also elevated.  PPARγ, ABCG1, and ABCA1 gene expression in 
alveolar macrophages from Lenti-eGFP instilled animals were not different from 
sham.  Increased expression of PPARγ, ABCG1, and ABCA1 protein was also 
determined by immunofluorescence (data not shown). 
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Figure 5.1  Lentivirus efficiently transduces alveolar macrophages in vivo.  
GM-CSF KO instilled with Lenti-eGFP in vivo exhibit eGFP positive cells at 10 
and 30 days post-instillation.  (A) Representative image of eGFP positive GM-
CSF KO alveolar macrophages.  (B) Cytospin preparations of BAL cells were 
counted for eGFP positivity. 
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Figure 5.2 PPARγ and cholesterol transporters ABCG1 and ABCA1 are up-
regulated.  (A) RT-PCR analysis demonstrated up-regulation of PPARγ, (B) 
ABCG1, and (C) ABCA1 mRNA in the alveolar macrophages of GM-CSF KO 
mice instilled with Lenti-PPARγ virus at 10 days post-instillation, compared to 
untreated animals.  RT-PCR values for GM-CSF KO mice instilled with control 
virus Lenti-eGFP were not different from untreated animals.  
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Cholesterol clearance from alveolar macrophages is increased.  The 
previously reported accumulation of cholesterol in the alveolar macrophages and 
BAL fluids of GM-CSF KO mice (110) together with our observations of 
decreased PPARγ and ABCG1 (51) suggested that cholesterol efflux to HDL 
might be impaired.  Having demonstrated the up-regulation of the cholesterol 
transporter ABCG1, we next investigated the cholesterol efflux in the alveolar 
macrophages of Lenti-PPARγ treated GM-CSF KO mice compared to 
macrophages from untreated animals.  The mean cholesterol efflux to HDL 
compared to basal efflux (no acceptor) was 1.4±3.3% in untreated GM-CSF 
macrophages whereas efflux in alveolar macrophages 10 days post-instillation 
was 6.0±0.9% (Figure 5.3A).  To further evaluate the clearance of cholesterol, we 
measured the intracellular neutral lipid accumulation at 10 days post-instillation 
with Lenti-PPARγ.  The intensity of Oil Red O staining was decreased in treated 
mice (Figure 5.3B).  Cell size of Lenti-PPARγ treated GM-CSF KO mice was also 
significantly reduced (data not shown).  Given enhanced cholesterol efflux and 
decreased cellular lipid accumulation, we speculated that extracellular 
cholesterol would be increased in the BAL fluid.  As expected, the extracellular 
cholesterol was increased (27±3 µg/mL) as compared to BAL fluid from untreated 
GM-CSF KO mice (12±0.2 µg/mL) (Figure 5.3C).  These results suggest PPARγ 
promotes cholesterol catabolism in alveolar macrophages through ABCG1.   
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Figure 5.3 Cholesterol clearance from alveolar macrophages is increased.   
(A) ABCG1-mediated cholesterol efflux to HDL is increased in the alveolar 
macrophages of GM-CSF KO mice instilled with Lenti-PPARγ.  (B)  
Representative images from alveolar macrophages stained with Oil Red O to 
detect neutral lipid accumulation show decreased intensity of Oil Red O staining 
in the alveolar macrophages treated with Lenti-PPARγ at 10 days post-instillation.   
(C)  Cholesterol accumulates in the BAL fluid of GM-CSF KO mice instilled with 
Lenti-PPARγ.   
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Discussion 
 
 Alternative therapies for PAP are needed, as less than 50% of patients 
treated with recombinant GM-CSF exhibit symptomatic and radiographic 
improvement (53,144,145).  Previous studies have suggested that the clearance 
of surfactant by alveolar macrophages is mediated by the GM-CSF-PPARγ 
pathway (6,7).  Our findings confirm PPARγ transcriptionally regulates surfactant 
catabolism in alveolar macrophages and provide evidence that PPARγ is a valid 
therapeutic target.  
 To address the role of PPARγ in surfactant catabolism, we have up-
regulated PPARγ in PPARγ-deficient alveolar macrophages of GM-CSF KO mice 
in vivo.  We have demonstrated increased expression of PPARγ and downstream 
targets ABCG1 and ABCA1.  Up-regulation of PPARγ and ABCG1 resulted in 
increased cholesterol efflux via the ABCG1-HDL pathway.  Neutral lipid 
accumulation was reduced in treated alveolar macrophages, as evidenced by Oil 
Red O.  Finally, free cholesterol was increased in the BAL fluid of treated GM-
CSF KO mice.  Taken together, these studies suggest that the expression 
PPARγ and ABCG1 in alveolar macrophages promotes the catabolism of 
surfactant, specifically the cholesterol component of surfactant.   
 PPARγ regulates the catabolism and transport of cholesterol in other 
tissue macrophages via the lipid transporters ABCG1 and ABCA1 (77,78).  The 
expression of PPARγ, ABCG1, and ABCA1 were increased in the alveolar 
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macrophages of GM-CSF KO mice treated with Lenti-PPARγ at 10 days post-
instillation.  These results are an extension of our previous results in which 
PPARγ and ABCG1 were deficient in GM-CSF KO alveolar macrophages.  
Replacement of PPARγ corrects these deficiencies and further links the PPARγ-
ABCG1 pathway in the catabolism of surfactant. 
Cholesterol is the major neutral lipid in surfactant.  Therefore, 
dysregulation of cholesterol catabolism in alveolar macrophages may have 
impacts on the clearance of surfactant overall.  We have shown that the alveolar 
macrophages of GM-CSF KO mice accumulate neutral lipids and are deficient in 
PPARγ (47).  We show that by restoring PPARγ in this system, there is a 
reduction in neutral lipid accumulation which we speculated was due to increased 
cholesterol efflux from the macrophages.  This was supported both by the 
increased ABCG1-HDL cholesterol efflux and elevated levels of extracellular 
cholesterol in Lenti-PPARγ treated GM-CSF KO mice. 
 Utilizing a Lenti-PPARγ virus, we restored expression of PPARγ in the 
PPARγ-deficient alveolar macrophages of GM-CSF KO mice.  Replacement of 
PPARγ resulted in increased expression of the cholesterol transporter ABCG1 
and decreased intracellular lipid accumulation, confirming our hypothesis.  Taken 
together, these studies directly link the expression of PPARγ and ABCG1 in the 
promotion of surfactant catabolism and may serve as potential therapeutic 
targets in the treatment of PAP.  
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 CHAPTER 6 
 
 
SUMMARY 
 
 The overall purpose of the studies described in Chapters 2-5 was to 
investigate the role of the nuclear transcription factor PPARγ in surfactant 
catabolism in alveolar macrophages.  This dissertation investigated the 
hypothesis that surfactant catabolism is regulated by the PPARγ-ABCG1 
pathway.  Chapters 2 and 4 detailed experiments which utilized a macrophage-
specific PPARγ KO mouse model and demonstrated the following: 
(1) PPARγ KO mice exhibit a PAP-like lung pathology with the accumulation 
of surfactant and the presence of foamy alveolar macrophages.  
(2) The deletion of PPARγ resulted in the dysregulation of ABC transporters 
and LXR transcription factors and reduced ABCG1-mediated cholesterol 
efflux. 
(3) In addition to dysregulated cholesterol efflux genes LXRα and ABCG1, the 
alveolar macrophages of PPARγ KO exhibited decreased expression of 
cholesterol biosynthesis gene SREBP2 and downstream targets HMGCR 
and LDL-R and increased expression of cholesterol scavenger receptors 
CD36 and SRA-I. 
(4) Replacement of PPARγ in vivo in PPARγ KO mice resulted in up-
regulation of cholesterol efflux genes LXRα and ABCG1, cholesterol 
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biosynthesis genes SREBP2 and HMGCR, and receptors LDL-R and 
CD36 in alveolar macrophages. 
Results from these studies indicate that PPARγ regulates surfactant catabolism 
through the regulation of LXR transcription factors and ABC lipid transporters in 
alveolar macrophages. 
 Chapter 5 relates experiments in which PPARγ expression was restored in 
vivo in the PPARγ-deficient alveolar macrophages of GM-CSF KO mice, the 
mouse model for the human lung disease PAP.  These experiments 
demonstrated the following: 
(1)  GM-CSF KO mice instilled in Lenti-PPARγ in vivo efficiently up-regulated 
PPARγ and ABCG1. 
(2) Expression of the PPARγ-ABCG1 pathway resulted in increased 
cholesterol efflux from GM-CSF KO alveolar macrophages.  
(3) Expression of PPARγ resulted in reduction of lipid-laden alveolar 
macrophages and increased extracellular cholesterol in the lungs of GM- 
CSF mice. 
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Macrophage-specific Deletion of PPARγ  
 
 Previous findings in our laboratory demonstrated that the alveolar 
macrophages of PAP patients and GM-CSF KO mice were deficient in PPARγ 
(6,51).  We utilized a macrophage-specific PPARγ KO mouse to investigate the 
role of PPARγ in alveolar macrophages and surfactant catabolism.  Interestingly, 
PPARγ KO mice developed pulmonary disease similar to that of PAP patients 
and GM-CSF KO mice with the accumulation of surfactant phospholipids, 
cholesterol, and associated proteins.  Additionally, the foamy, lipid-laden alveolar 
macrophages of PPARγ KO mice phenotypically resembled those of PAP 
patients and GM-CSF KO mice. This is the first report directly linking the 
deficiency of PPARγ in alveolar macrophages to the accumulation of surfactant.    
 Consistent with PAP patients and GM-CSF KO mice (51), the expression 
of ABCG1 was decreased and ABCA1 increased in alveolar macrophages of 
PPARγ KO mice.  Functional analyses of the transporters corresponded to gene 
expression in that PPARγ KO alveolar macrophages exhibited decreased 
ABCG1-mediated cholesterol efflux and increased ABCA1-mediated efflux.  
These results may reflect a compensatory mechanism in which the deficiency of 
one ABC transporter results in PPARγ and LXR ligand accumulation leading to 
the induction of the other transporter (86,87).  However, it has been suggested, 
and our results provide further evidence, that the induction of ABCA1 is less 
efficient at compensating for the loss of ABCG1, as ABCG1-deficient mice 
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develop more severe lipid accumulation in the lung than ABCA1 knockout 
models (86,89,90).  Our results indicate that ABCG1-mediated cholesterol efflux 
to HDL may be the major pathway for cholesterol efflux in alveolar macrophages.    
An important, unexpected difference emerged from the study of PPARγ 
KO alveolar macrophages from what has been published previously on PAP 
patients and GM-CSF KO mice: LXRα expression was increased in PAP and 
GM-CSF KO (51) but decreased in PPARγ KO.  We postulate that this difference 
is due to the fact that PPARγ is not completely absent in PAP patients and GM-
CSF KO mice.  Indeed, upon restoration of PPARγ in PPARγ KO mice, LXRα 
expression was induced.  Although regulated by additional independent 
mechanisms, LXRα is directly regulated by PPARγ.  Chawla, et al. concluded 
that PPARγ is an essential regulator of cholesterol metabolism in arterial 
macrophages (146) and our findings indicate the same is true in alveolar 
macrophages.   
 Although the expression of LXRβ has not been reported in PAP or GM-
CSF KO, we demonstrated that LXRβ was up-regulated in PPARγ KO alveolar 
macrophages.  While LXRα is typically regarded as the predominant isoform in 
the cholesterol efflux pathway in macrophages, both LXRα and LXRβ have been 
reported to transcriptionally promote genes involved in cholesterol efflux.  The 
transcriptional efficiency and tissue-specificity of the individual isoforms remain in 
question (101,113-115,147).  Importantly, LXRβ has been shown to be regulated 
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independently of PPARγ and thereby represents a PPARγ-independent pathway 
in the transcriptional promotion of cholesterol efflux from macrophages (146).   
 Interest in differentiating the LXR isoforms has increased due to the 
potential therapeutic application for atherosclerosis.  For example, ligand 
activation of LXRβ reduced atherosclerosis in the vascular tissue of mice lacking 
LXRα (148).  However, unlike LXRα, specific activation of LXRβ did not result in 
increased triglyceride production (149,150).  The contribution of the individual 
LXR isoforms in surfactant catabolism is unknown and warrants further 
investigation.   
 While the LXR pathway is enhanced, as evidenced by increased 
expression of LXRβ, ABCA1, ApoE, and CYP27A1, surfactant accumulates in 
PPARγ KO mice suggesting this pathway is not sufficient to maintain surfactant 
catabolism in the absence of PPARγ.  Additionally, this data indicates LXRβ is 
responsive to intracellular oxysterol build-up and may also reflect the presence of 
LXRβ-specific ligand.  Increased basal expression of LXRβ was unexpected and 
to our knowledge has not been observed in other tissues that express both 
isoforms.  For example, the hepatic tissues of LXRα KO mice did not exhibit 
compensatory LXRβ expression (147).  Increased expression of LXRβ in the 
alveolar macrophages of PPARγ KO mice may demonstrate site and/or cell 
specific differences.  The deficiencies of transcription factors PPARγ and LXRα 
and cholesterol transporter ABCG1 and the resulting accumulation of various 
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surfactant components in PPARγ KO mice emphasize the importance of 
cholesterol catabolism in the overall clearance of surfactant.    
 Several comprehensive reviews have suggested that the PPARγ-LXR 
pathway is the link between lipid metabolism and inflammation in macrophages 
(151,152).  Studies presented in this thesis demonstrate that PPARγ regulates 
lipid metabolism in alveolar macrophages.  We have also recently reported that 
the alveolar macrophages of PPARγ KO mice exhibit increased expression of 
pro-inflammatory Th-1 associated cytokines (96).  Although the presence of 
modified-LDL in the lungs of PPARγ KO mice has not been determined, research 
in the field of atherosclerosis has shown that foam cell phenotype, the 
accumulation of cholesterol, and a pro-inflammatory state are indicative of 
increased uptake of modified-LDL (7).  We have presented indirect evidence 
supporting the presence of modified-LDL in the lungs of PPARγ KO mice.  First, 
enhanced expression of scavenger receptors CD36 and SRA-I indicate the 
increased presence of substrate (modified-LDL).  Secondly, the accumulation of 
predominantly free cholesterol in the alveolar macrophages of PPARγ KO mirrors 
the late atherosclerotic event in which free cholesterol deposition results from 
insufficient cholesterol hydrolysis in lysosomes due to oxidized-LDL particles 
(64).  Finally, data from Yvan-Charvet and colleagues have suggested ABCG1 
has a specific role of protecting the lungs from oxidized sterol accumulation 
(86,153).  ABCA1-deficient macrophages treated with oxidized-LDL rapidly 
underwent apoptosis but the addition of HDL significantly decreased the 
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percentage of cells undergoing apoptosis.  Therefore, the reduced expression of 
ABCG1 in PPARγ KO alveolar macrophages may have deleterious effects on the 
accumulation of oxidized sterols.   
 Our findings indicate that a combination of decreased cholesterol efflux 
and increased uptake of modified-LDL by scavenger receptors contributed to 
cholesterol overload and foam cell formation in the alveolar macrophages of 
PPARγ KO mice.  We speculate that insufficient catabolism of cholesterol derived 
from modified-LDL impairs the overall catabolism of surfactant in alveolar 
macrophages.  Similar to other tissue macrophages, the influx and efflux of 
cholesterol in alveolar macrophages appears to be regulated by PPARγ.  
However, the lung is a cholesterol-rich environment and the maintenance of 
cholesterol catabolism is critical.  While the changes in the lungs of PPARγ KO 
mice cannot be attributed to a single mechanism, the abundance of cholesterol 
indicates cholesterol may contribute to the dysregulated state of surfactant 
catabolism.   
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Restoration of PPARγ in GM-CSF KO Mice  
 
 To further investigate the PPARγ-ABCG1 pathway in the catabolism of 
surfactant, we next reconstituted PPARγ expression in GM-CSF KO mice in vivo 
using the retroviral vector Lenti-PPARγ.  Ten days post-instillation of Lenti-
PPARγ, we measured increased expression of PPARγ and ABCG1 in the GM-
CSF KO alveolar macrophages.  Correlating to the up-regulation of the 
cholesterol transporter ABCG1, ABCG1-mediated cholesterol efflux was 
increased.  These results corresponded to decreased intracellular neutral lipid 
accumulation and increased extracellular cholesterol levels to suggest that 
cholesterol catabolism was enhanced in vivo in treated alveolar macrophages.  
These results provide further evidence that PPARγ transcriptionally regulates 
ABCG1 and thereby promotes cholesterol catabolism in alveolar macrophages.   
 Extrapolating from the GM-CSF KO model, our results suggest that foam 
cell formation and the accumulation of cholesterol in the lungs of PAP patients 
resulted from deficiencies in PPARγ and ABCG1 and perhaps contributed to the 
accumulation of surfactant overall.  This data extends our previous results and 
indicates that the GM-CSF-PPARγ pathway regulates surfactant clearance in 
alveolar macrophages through the ABCG1 lipid transporter. 
 It has been clearly demonstrated that GM-CSF is a critical mediator of 
surfactant homeostasis in alveolar macrophages.  Our work has continued this 
pathway to include PPARγ and ABCG1.  Alternative therapies are needed, as 
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treatment with recombinant GM-CSF results in symptomatic or radiographic 
improvement in approximately 50% of PAP patients (53,144,145).  A follow-up 
study demonstrated that non-responding patients have high titers of neutralizing 
GM-CSF auto-antibodies which may be too high for exogenous GM-CSF 
treatments to overcome (54).  In clinical trials, PAP patients were treated with 
higher doses of GM-CSF than current dose recommendations to reduce the 
duration and degree of neutropenia in certain cancer patients undergoing 
chemotherapy (53).  While there is no evidence to suggest that PAP patients 
increase production of neutralizing antibodies in response to GM-CSF treatment 
(53), the possibility remains that increasing doses of antigen could stimulate 
antibody production.  Taken together, this suggests PPARγ may be a more 
suitable therapeutic target than GM-CSF for PAP.   
 PPARγ agonist rosiglitazone may confer additional anti-inflammatory 
properties through the activation of PPARγ.  In fact, PPARγ agonists have been 
shown to diminish inflammatory responses in murine models of asthma (154) and 
improve lung function in corticosteroid-resistant asthma patients (155).  
Decreased levels of PPARγ protein in the alveolar macrophages of PAP patients 
may attenuate the effects of PPARγ agonists.  However, recent in vitro models 
have demonstrated that the presence of synthetic and natural PPARγ ligands up-
regulates the expression of PPARγ likely through downstream positive feedback 
mechanisms (156).  While currently only conjecture, PPARγ may prove to be a 
more suitable target for the treatment of PAP.  Our work, however, confirms 
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PPARγ regulates surfactant catabolism in alveolar macrophages and provides 
evidence that PPARγ is a valid therapeutic target. 
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Future Directions 
 
 Several questions arise from the work reported in this thesis.  First, one 
major difference between PPARγ KO and GM-CSF KO mice is the presence of 
GM-CSF.  GM-CSF is a hematopoietic growth factor that promotes cell survival 
and proliferation and has a specific role in the differentiation of alveolar 
macrophages (7,29,102).  One explanation for why GM-CSF deficiency only 
disrupts the terminal differentiation of alveolar macrophages is the expression of 
the transcription factor PU.1 (41).  PU.1 promotes differentiation in several 
hematopoetic lineages including alveolar macrophages, unlike other tissue 
macrophages (104,157).   
 The alveolar macrophages of PAP patients and GM-CSF KO mice have 
significantly reduced levels of PU.1 (103,104).  The alveolar macrophages from 
GM-CSF KO mice do not express differentiation marker CD11c (158,159), and 
PU.1-dependent terminal differentiation markers CD32, mannose receptor (MR), 
and macrophage colony-stimulating factor receptor (MCSFR) are reduced in the 
alveolar macrophages of PAP patients and GM-CSF KO mice (103,104).  
Replacement of PU.1 in GM-CSF KO mice corrected surfactant catabolism (3). 
 While induced upon differentiation into macrophages (160), PPARγ is not 
required for the differentiation of macrophages (100).  Further, the expression of 
GM-CSF and PU.1 is not deficient in the alveolar macrophages of PPARγ KO 
mice.  This suggests the differentiation and maturation of the PPARγ KO alveolar 
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macrophages is not affected as with GM-CSF KO mice.  Several cell-surface 
markers of macrophage maturation and differentiation, such as those mentioned 
above, could be analyzed by flow cytometry to conclusively address the 
differentiation of PPARγ KO alveolar macrophages.    
 Another area of interest stemming from this work is the relationship 
between lipid accumulation and inflammation in PPARγ KO mice.  Several 
comprehensive reviews have suggested that the PPARγ-LXR pathway is the link 
between lipid metabolism and inflammation in macrophages (151,152).  Herein 
we have demonstrated that PPARγ regulates lipid metabolism in alveolar 
macrophages.  We have also recently reported that the alveolar macrophages of 
PPARγ KO mice exhibit increased expression of Th-1 associated pro-
inflammatory cytokines (96).  It is unclear whether the deficiency of PPARγ 
resulted in lipid accumulation which lead to inflammation or if it was the 
production of inflammatory mediators that lead to lipid accumulation.   
 To address this question, we would first investigate the presence of pro-
inflammatory cytokines and surfactant accumulation in younger PPARγ KO mice 
than the 8-12 week old mice utilized in the present studies.  As GM-CSF KO 
mice develop pulmonary disease by 3 weeks of age (30), studying 3-6 week old 
PPARγ KO mice may clarify the onset of surfactant accumulation and 
inflammatory responses.  Since it is unlikely that the results from these 
experiments would be definitive, additional in vitro experiments would be needed.  
For example, we could compare the inflammatory response elicited from 
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cholesterol-depleted wild type and PPARγ KO alveolar macrophages, by 
treatment with methyl-beta-cyclodextrin, cultured in the presence surfactant and 
an inflammatory agent such as lipopolysaccharide (161,162).  Understanding the 
complex progression of lipid accumulation and inflammation in PPARγ KO mice 
is critical to the study of the regulation of surfactant metabolism in a broader 
context. 
 We have demonstrated that the alveolar macrophages of PPARγ KO mice 
develop cholesterol-laden alveolar macrophages that exhibit a foam cell 
phenotype.  Free cholesterol comprised the bulk of the intracellular cholesterol 
accumulation.  Importantly, the source of accumulating cholesterol (ie, LDL-
derived or modified-LDL-derived) is a major factor in the storage and metabolism 
of the cholesterol.  Cholesterol derived from modified-LDL is poorly catabolized 
and can result in the accumulation of free cholesterol which can disrupt cell 
signaling, cause plasma membrane rigidity, and induce pro-apoptotic cascades 
(163).  The presence of modified-LDL can be indirectly determined utilizing 
several protocols to detect the presence of modified-LDL antibodies in sera 
(164,165).  Alternatively, antibodies against modified-LDL could be used to 
measure the protein directly (166,167).   
 We propose that insufficient catabolism of cholesterol derived from 
modified-LDL impairs the overall catabolism of surfactant.  Phospholipid efflux 
studies on the alveolar macrophages of PPARγ KO mice, if found to be similar to 
wild type, could confirm specific defects in the regulation of cholesterol.  These 
142 
findings would have implications in the study of PPARγ and human lung diseases 
associated with surfactant accumulation. 
Finally, the maintenance of cholesterol efflux is a crucial part of cholesterol 
homeostasis and is essential in the prevention of foam cell formation (77,168).  
The results presented in this thesis suggest that ABCG1-mediated cholesterol 
efflux is especially critical to the catabolism of surfactant in the alveolar 
macrophage.  We have demonstrated that PPARγ KO alveolar macrophages 
exhibit reduced ABCG1 and ABCG1 cholesterol efflux.  Replacement of PPARγ 
in GM-CSF KO mice induced expression of ABCG1 and increased ABCG1-
mediated cholesterol efflux.  The next step in developing the PPARγ-ABCG1 
pathway would be to silence ABCG1 expression using small interfering RNA 
(siRNA) in wild type alveolar macrophages and measure the efflux of cholesterol 
to serum as a measure of maximum cholesterol efflux potential and to specific 
ABCG1-mediated efflux HDL.  If reduced, this would indicate ABCG1 is a major 
contributor to cholesterol efflux from alveolar macrophages.  LXR agonists could 
be used in conjunction with ABCG1 siRNA to induce ABCA1 expression to reflect 
conditions in PPARγ KO alveolar macrophages.    
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Conclusions 
 
The work presented in this dissertation addresses the role of PPARγ in 
surfactant catabolism in alveolar macrophages.  We hypothesized that PPARγ 
promotes surfactant catabolism by the regulation of ABCG1 and that the up-
regulation of PPARγ will increase surfactant catabolism in PPARγ-deficient 
alveolar macrophages and reduce the presence of lipid-engorged alveolar 
macrophages in the lung.   
We show that the targeted knockout of PPARγ in macrophages resulted in 
the accumulation of surfactant in the alveolar spaces of the lung and within the 
alveolar macrophages, reduced expression of ABCG1, and reduced ABCG1-
mediated cholesterol efflux.  These results support the hypothesis and directly 
link the deficiency of PPARγ to lipid accumulation in the lung.   
To study the effects of PPARγ replacement on surfactant catabolism in 
PPARγ-deficient alveolar macrophages in vivo, we developed an efficient 
Lentivirus expression system to up-regulate PPARγ.  Replacement of PPARγ in 
GM-CSF KO mice resulted in increased expression of ABCG1, enhanced 
ABCG1-mediated cholesterol efflux, and reduced intracellular lipid accumulation.   
Results from all sets of experiments suggest that PPARγ mediates a critical role 
in surfactant homeostasis through the regulation of ABCG1.  These findings have 
potential implications in lung diseases such as PAP in which surfactant 
accumulates and PPARγ and ABCG1 are deficient in alveolar macrophages.  
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Understanding the role of PPARγ in normal surfactant homeostasis provides 
insight into the pathophysiology of PAP and identifies a potential therapeutic 
target.  
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